Synergetics Usa 10-K 14 Oct 14 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Jul. 31, 2014	Oct. 10, 2014	Jan. 31, 2014
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'SYNERGETICS USA INC	'	'
Entity Central Index Key	'0000836429	'	'
Current Fiscal Year End Date	'--07-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$66,981,524
Entity Common Stock, Shares Outstanding	'	25,364,608	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'FY	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Jul-14	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jul. 31, 2014	Jul. 31, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$15,443	$12,470
Accounts receivable, net of allowance for doubtful accounts of $722 and $495, respectively	14,641	14,425
Inventories	15,134	14,825
Income taxes refundable	0	254
Prepaid expenses	1,223	996
Deferred income taxes	2,042	1,827
Total current assets	48,483	44,797
Property and Equipment, net	8,785	8,962
Intangible and Other Assets	'	'
Goodwill	12,738	12,155
Other intangible assets, net	11,911	11,715
Deferred income taxes	1,219	3,557
Patents, net	1,472	1,411
Cash value of life insurance	107	96
Total assets	84,715	82,693
Current Liabilities	'	'
Accounts payable	2,530	3,237
Accrued expenses	2,845	3,486
Income taxes payable	386	0
Deferred revenue	1,288	1,288
Total current liabilities	7,049	8,011
Long-term liabilities	'	'
Deferred revenue	13,242	14,530
Total long-term liabilities	13,242	14,530
Total liabilities	20,291	22,541
Commitments and Contingencies (Notes 11 and 18)	'	'
Stockholders' equity	'	'
Common stock at July 31, 2014 and July 31, 2013, $0.001 par value, 50,000,000 shares authorized; 25,364,608 and 25,292,960 shares issued and outstanding, respectively	25	25
Additional paid-in capital	28,594	27,489
Retained earnings	36,160	33,097
Accumulated other comprehensive loss:	'	'
Foreign currency translation adjustment	-355	-459
Total stockholders' equity	64,424	60,152
Total liabilities and stockholders' equity	$84,715	$82,693

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Jul. 31, 2014	Jul. 31, 2013
In Thousands, except Share data, unless otherwise specified
Current assets	'	'
Accounts receivable, allowance for doubtful accounts	$722	$495
Stockholders' equity	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	25,364,608	25,292,960
Common stock, shares outstanding (in shares)	25,364,608	25,292,960

Consolidated_Statements_of_Inc

Consolidated Statements of Income and Comprehensive Income (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012
Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) [Abstract]	'	'	'
Net sales	$64,769	$62,796	$60,014
Cost of sales	28,540	30,425	25,495
Gross profit	36,229	32,371	34,519
Operating expenses	'	'	'
Research and development	5,158	3,643	3,642
Sales and marketing	14,360	13,805	11,881
Medical device excise tax	486	289	0
Exit costs	682	0	0
General and administrative	10,962	10,913	10,515
Total operating expenses	31,648	28,650	26,038
Operating income	4,581	3,721	8,481
Other income (expenses)	'	'	'
Investment income	10	31	40
Interest expense	-19	-28	-43
Miscellaneous	-11	-35	-11
Total other income (expenses)	-20	-32	-14
Income from continuing operations before provision for income taxes	4,561	3,689	8,467
Provision for income taxes	1,498	1,130	2,499
Income from continuing operations	3,063	2,559	5,968
Loss from discontinued operations, net of income tax benefit of $--, $-- and $193, respectively	0	0	382
Net income	3,063	2,559	5,586
Basic	'	'	'
Income from continuing operations (in dollars per share)	$0.12	$0.10	$0.24
Loss from discontinued operations (in dollars per share)	$0	$0	($0.02)
Net income (in dollars per share)	$0.12	$0.10	$0.22
Diluted	'	'	'
Income from continuing operations (in dollars per share)	$0.12	$0.10	$0.24
Loss from discontinued operations (in dollars per share)	$0	$0	($0.02)
Net income (in dollars per share)	$0.12	$0.10	$0.22
Basic weighted average common shares outstanding (in share)	25,323,622	25,243,010	25,100,064
Diluted weighted average common shares outstanding (in share)	25,393,264	25,337,525	25,256,584
Net income	3,063	2,559	5,586
Foreign currency translation adjustment	104	47	-595
Comprehensive income	$3,167	$2,606	$4,991

Consolidated_Statements_of_Inc1

Consolidated Statements of Income and Comprehensive Income (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012
Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) [Abstract]	'	'	'
Loss from discontinued operations, net of income tax benefit	$0	$0	$193

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
In Thousands, except Share data, unless otherwise specified
Balance at Jul. 31, 2011	$25	$25,598	$24,952	$89	$50,664
Balance (in shares) at Jul. 31, 2011	24,970,884	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Net income	0	0	5,586	0	5,586
Foreign currency translation adjustment	0	0	0	-595	-595
Restricted stock grants	0	336	0	0	336
Restricted stock grants (in shares)	166,707	'	'	'	'
Stock-based compensation	0	428	0	0	428
Stock-based compensation (in shares)	5,593	'	'	'	'
Proceeds from stock options exercised	0	35	0	0	35
Proceeds from stock options exercised (in shares)	16,885	'	'	'	'
Tax benefit associated with stock options exercised	0	24	0	0	24
Balance at Jul. 31, 2012	25	26,421	30,538	-506	56,478
Balance (in shares) at Jul. 31, 2012	25,160,069	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Net income	0	0	2,559	0	2,559
Foreign currency translation adjustment	0	0	0	47	47
Restricted stock grants	0	293	0	0	293
Restricted stock grants (in shares)	58,272	'	'	'	'
Stock-based compensation	0	638	0	0	638
Stock-based compensation (in shares)	15,309	'	'	'	'
Proceeds from stock options exercised	0	65	0	0	65
Proceeds from stock options exercised (in shares)	59,310	'	'	'	'
Tax benefit associated with stock options exercised	0	72	0	0	72
Balance at Jul. 31, 2013	25	27,489	33,097	-459	60,152
Balance (in shares) at Jul. 31, 2013	25,292,960	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'
Net income	0	0	3,063	0	3,063
Foreign currency translation adjustment	0	0	0	104	104
Restricted stock grants	0	426	0	0	426
Restricted stock grants (in shares)	7,000	'	'	'	'
Stock-based compensation	0	582	0	0	582
Stock-based compensation (in shares)	14,648	'	'	'	'
Proceeds from stock options exercised	0	59	0	0	59
Proceeds from stock options exercised (in shares)	50,000	'	'	'	'
Tax benefit associated with stock options exercised	0	38	0	0	38
Balance at Jul. 31, 2014	$25	$28,594	$36,160	($355)	$64,424
Balance (in shares) at Jul. 31, 2014	25,364,608	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012
Cash flows from operating activities	'	'	'
Net income	$3,063	$2,559	$5,586
Plus: Loss from discontinued operations - net of tax	0	0	382
Income from continuing operations	3,063	2,559	5,968
Adjustments to reconcile net income to net cash provided by (used in) operating activities	'	'	'
Depreciation	1,173	1,123	1,093
Amortization	876	680	600
Provision for doubtful accounts receivable	338	207	50
Stock-based compensation	1,008	931	764
Deferred income taxes	1,836	-49	153
(Gain) loss on sale of equipment	-10	35	0
(Increases) decreases in:	'	'	'
Accounts receivable	-406	-2,553	-843
Inventories	179	1,191	-3,695
Prepaid expenses	-221	-130	93
Income taxes refundable	254	-254	219
Increases (decreases) in:	'	'	'
Accounts payable	-849	845	615
Accrued expenses	-667	603	-183
Deferred revenue	-1,288	-1,288	-1,494
Income taxes payable	380	-235	-5,848
Net cash provided by (used in) operating activities	5,666	3,665	-2,508
Net cash provided by discontinued operations	0	0	59
Net cash provided by (used in) operating activities	5,666	3,665	-2,449
Cash flows from investing activities	'	'	'
Proceeds on the sale of equipment	18	55	0
Purchase of property and equipment	-922	-550	-1,809
Acquisition of patents and other intangibles	-258	-412	-214
Acquisitions, less cash acquired	-1,387	-2,848	0
Increase in cash value of life insurance	-11	-3	-11
Net cash used in investing activities	-2,560	-3,758	-2,034
Cash flows from financing activities	'	'	'
Payment on debt incurred for acquisition of trademark	0	0	-313
Principal payments on long-term debt	0	0	-740
Tax benefit associated with the exercise of non-qualified stock options	38	72	24
Proceeds from the issuance of common stock	59	65	35
Net cash provided by (used in) financing activities	97	137	-994
Foreign exchange rate effect on cash and cash equivalents	-230	-254	-242
Net increase (decrease) in cash and cash equivalents	2,973	-210	-5,719
Cash and cash equivalents	'	'	'
Beginning	12,470	12,680	18,399
Ending	15,443	12,470	12,680
Cash paid for:	'	'	'
Interest	19	28	63
Income taxes (received) paid	-1,009	1,568	7,950
Supplemental Schedule of Non-cash Investing and Financing Activity	'	'	'
Purchase of equipment included in accounts payable	$17	$120	$0

Nature_of_Business_and_Signifi

Nature of Business and Significant Accounting Policies	12 Months Ended
	Jul. 31, 2014
Nature of Business and Significant Accounting Policies [Abstract]	'
Nature of Business and Significant Accounting Policies	'
	Note 1. Nature of Business and Significant Accounting Policies
	Nature of business: Synergetics USA, Inc. (“Synergetics USA” or the “Company”) is a Delaware corporation incorporated on June 2, 2005, in connection with the reverse merger of Synergetics, Inc. (“Synergetics”) and Valley Forge Scientific Corp. (“Valley Forge”) and the subsequent reincorporation of Valley Forge (the predecessor to Synergetics USA) in Delaware. Synergetics USA is a leading supplier of precision surgical devices.  Through continuous improvement and development of its people, the Company’s mission is to design, manufacture and market innovative surgical devices, surgical equipment and consumables of the highest quality in order to assist and enable surgeons who perform surgery around the world to provide a better quality of life for their patients.   The Company’s primary focus is on targeted segments within the surgical disciplines of ophthalmology and neurosurgery. Its distribution channels include a combination of direct and independent distributor sales organizations and important strategic alliances with market leaders. The Company is located in O’Fallon, Missouri, King of Prussia, Pennsylvania, California and Corby, United Kingdom.  During the ordinary course of its business, the Company grants unsecured credit to its domestic and international customers.
	A summary of the Company’s significant accounting policies follows:
	Use of estimates in the preparation of financial statements: The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.
	Principles of consolidation: The consolidated financial statements include the accounts of Synergetics USA and its wholly owned subsidiaries: Synergetics, Synergetics IP, Inc., Synergetics Development Company, LLC and Synergetics Delaware, Inc.  All significant intercompany accounts and transactions have been eliminated.
	Cash and cash equivalents: For purposes of the consolidated statements of cash flows, the Company considers all highly liquid debt instruments purchased with maturity of three months or less to be cash equivalents.
	Accounts receivable: During the ordinary course of its business, the Company grants unsecured credit to its domestic and international customers.  Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis.  Collateral is not generally required on the Company’s accounts receivable.  Accounts receivable are generally considered past due based upon their specific terms.  Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions.  Accounts receivable are written off when deemed uncollectible.  Recoveries of accounts receivable previously written off are recorded when received.  The Company generally does not charge interest on past-due amounts in accounts receivable.  The Company has a history of minimal uncollectible accounts.
	Concentration of credit risk: Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and accounts receivable.  The Company’s cash and cash equivalents are primarily held in a money market account in a bank and currently exceed the FDIC insurance limit.  Generally these deposits can be redeemed upon demand and therefore, bear minimal risk.
	Inventories: Inventories, consisting of purchased materials, direct labor and manufacturing overhead, are stated at the lower of cost or market, with cost being determined using the first-in, first-out method. The Company’s inventory is very dynamic and new products are added frequently.  Thus, the Company reviews the valuation of its inventory on a quarterly basis and determines if a valuation allowance is necessary for items, including any excess quantities and identified obsolescence.  The Company monitors inventory activity by product type and uses both quantitative and qualitative factors to access the need for a reserve. The inventory analysis takes into account historical experience, the inventory’s length of time on hand, historical sales, product life cycle and product obsolescence. To the extent that the Company determines there are some excess quantities based on its projected levels of sales and other requirements, or obsolete material in inventory, the Company records a valuation reserve against all or a portion of the value of the related parts or products. If future cost valuations, future demand or market conditions are different from the Company’s projections, a change in recorded inventory reserve may be required and would be reflected in cost of sales in the period the revision is made.
	During the second quarter of fiscal 2013, the Company completed a detailed analysis of its inventory and recorded a reserve for excess inventory of approximately $1.6 million.  In its continuous effort to manage its inventory, the Company had previously conducted an inventory analysis of obsolete inventory and recorded a provision for same in the third quarter of fiscal 2012.   The reserve was necessary to reflect not only the Company’s changing base ophthalmic business but also to reflect the appropriate level and mix identified in accordance with the Company’s continuous improvement methodology with respect to its inventory.
	Property and equipment: Property and equipment are depreciated using the straight-line method over their estimated useful lives as follows:
		Useful lives (in years)
	Building and improvements	Jul-39
	Machinery and equipment	7-May
	Furniture and fixtures	7-May
	Software	10-Mar
	Goodwill and other intangibles: Absent any impairment indicators, goodwill is tested for impairment on an annual basis.  The Company performs its goodwill impairment tests during the fourth fiscal quarter.  The Company has adopted the provisions of Accounting Standards Update (“ASU”) No. 2011-08, “Intangibles – Goodwill and Other:  Testing Goodwill for Impairment” and ASU No. 2012-12, “Intangibles – Goodwill and Other:  Testing Indefinite-Lived Intangible Assets for Impairment,” which permits the Company to assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that goodwill and other intangibles have been impaired.  The Company has determined, based upon an assessment of qualitative factors, that it is more likely than not that goodwill and other intangibles have not been impaired and no further testing was performed as of July 31, 2014.  Other intangible assets, consisting of licensing agreements, proprietary know-how and customer relationships, are amortized to operations under the straight-line method over their estimated useful lives or statutory lives, whichever is shorter.  These periods range from three to fifteen years.  The life of a trademark is inextricably related to the life of the product bearing the mark or the life of the business entity owning the trademark.  The Company intends to use the Malis® trademark indefinitely, and therefore, its useful life is not limited to any specific product. The trademark constitutes an indefinite-lived intangible that will be used in perpetuity.  Proprietary know-how consists of the patented technology which is included in the Company’s core product lines, bipolar electrosurgical generators. The Company also recorded intangible assets related to proprietary know-how and customer relationships in relation to its two recent acquisitions. Proprietary technology and expertise are distinguishing features of the Company’s products and represent a valuable intangible asset.
	Patents: Incremental legal and other costs to obtain the patent are capitalized to a patent asset.  Salaries, benefits and other direct costs of product development are expensed as operating expenses in research and development (“R&D”) costs.  Patents are amortized to operations under the straight-line method over the remaining statutory life of the patent.
	Deferred revenue: During the second quarter of fiscal 2011, the Company received a payment from Codman & Shurtleff, Inc. (“Codman”), an original equipment manufacturer (“OEM”) partner, to establish exclusivity on certain generator products and accessories.  Revenue from the agreement has been deferred and is being amortized over its expected term.  The Company recognized $0, $0 and $266,000 in revenue for the fiscal years ended July 31, 2014, 2013 and 2012, respectively, under the terms of the exclusivity agreement.
	On April 23, 2010, the Company entered into a Settlement and License Agreement with Alcon, Inc. (“Alcon”)  pursuant to which Alcon paid to the Company $32.0 million. The net proceeds to the Company were $21.4 million after contingency payments to attorneys. The Company recognized a gain from this agreement of $2.4 million in the third quarter of fiscal 2010. The remaining $19.0 million has been accounted for as an up-front license fee under the Confidential Settlement and License Agreement and was deferred and recognized as earned over a period estimated to be 15 years based upon estimated shipments to Alcon under a related Supply Agreement.  On February 13, 2012, Alcon informed the Company that it had decided to cancel the project, orders and forecasts covering the two products to have been supplied under the Supply Agreement. However, the Supply Agreement remains in effect and the Company has continuing performance obligations associated with the Supply Agreement. Therefore, the Company plans to recognize the remaining deferred revenue associated with the Supply Agreement ratably over the next 12 years which is the remaining life of the patents and associated Supply Agreement. The Company recognized $1.3 million, $1.3 million and $1.2 million of this deferred revenue for the fiscal years ended July 31, 2014, 2013 and 2012, respectively.
			31-Jul-14		31-Jul-13
	Deferred revenue – Alcon settlement		$	14,530	$	15,818
	Less:  Short-term			1,288		1,288
	Long-term portion		$	13,242	$	14,530
	Impairment of long-lived assets (excluding goodwill and other intangibles): The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted cash flows expected to be generated by the asset.  Measurement of an impairment loss for long-lived assets and certain identifiable assets that management expects to hold and use is based on the fair value of the asset.  Assets to be sold are reported at the lower of the carrying amount or the fair value less costs to sell.
	Product warranty: The Company provides a warranty against manufacturing and workmanship defects. Under the Company’s general terms and conditions of sale, liability during the warranty period (typically three years) is limited to repair or replacement of the defective item. The Company’s warranty cost is not material.
	Income taxes: The Company accounts for income taxes under Accounting Standards Codification Topic 740, “Income Taxes” (“ASC Topic 740”).  Under ASC Topic 740, the deferred tax provision is determined using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss, tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences.  Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases.  Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.  Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
	In addition, under ASC Topic 740, the Company may recognize tax liabilities when, despite the Company’s belief that its tax return positions are supported, the Company believes that certain positions may not be fully sustained upon review by tax authorities.  The Company has identified no uncertain tax positions subsequent to the adoption of this standard on August 1, 2007.
	The Company’s policy is to recognize interest and penalties through income tax expense.  As of July 31, 2014, the 2011 to 2013 tax years remain subject to examination by major tax jurisdictions.  There are no federal income tax audits in process as of July 31, 2014. There is one state audit currently in progress.
	Fair value of financial instruments: The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses.  As of July 31, 2014, and 2013, the carrying amounts of financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate fair value due to the short maturity of these instruments.
	Non-financial assets such as goodwill, intangible assets and property, plant and equipment are measured at fair value when there is an indicator of impairment and recorded at fair value only when impairment is recognized.  No impairment indicators existed as of July 31, 2014.
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).  The fair value hierarchy consists of these broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).  The Company’s Level 1 financial assets are money market funds, whose fair values are based on quoted market prices. The Company does not have any Level 2 or Level 3 financial assets.
	Foreign currency translation:  All balance sheet accounts have been translated using the exchange rates in effect at the balance sheet date.  Statement of income amounts have been translated using the average exchange rate for the year.  The gains and losses resulting from the changes in exchange rates from year to year have been reported in other comprehensive income (loss).  The foreign currency translation adjustment is the only component of accumulated other comprehensive loss.  Foreign currency translation adjustments exclude income tax expense (benefit) given that the Company’s investments in foreign subsidiaries are deemed to be reinvested for an indefinite period of time.
	Revenue recognition: The Company primarily records revenue from product sales when the revenue is realized and the product is shipped from its facilities.  This includes satisfying the following criteria: the arrangement with the customer is evident, usually through the receipt of a purchase order; the sales price is fixed and determinable; delivery to the carrier has occurred; and collectability is reasonably assured. Freight and insurance billed to customers is included in net sales, and the cost of freight and insurance is included in cost of sales.  Sales tax billed to customers is included as a liability as products are shipped.
	The terms and conditions of sales to both the Company’s domestic and international distributors do not differ materially from the terms and conditions of sales to its domestic and international end-user customers.
	Service revenue substantially relates to repairs of products and is recognized when the service has been completed.  Revenue from royalty fees is recorded as the products bearing the trademark are shipped.
	Advertising: The Company follows the policy of charging the costs of advertising to expense as incurred. Advertising expense was approximately $197,000, $146,000 and $153,000 for the years ended July 31, 2014, 2013 and 2012, respectively.
	Royalties: The Company pays royalties to doctors and medical institutions for providing assistance in the design and development of various devices and components.  Royalties are paid quarterly based on the sales of the instrument or components.  Royalty expense was approximately $346,000, $331,000 and $282,000 for the years ended July 31, 2014, 2013 and 2012, respectively.
	Stock compensation: The Company has a stock plan for employees and consultants allowing for the grant of incentive and non-qualified stock options, restricted stock and stock awards. In addition, the Company has a stock option plan for non-employee directors allowing for non-qualified stock options.  Options under this plan have been granted to all non-employee directors.  Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the directors’ and employees’ requisite service periods. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options and grant-date market value to determine the fair value of the restricted stock awards.
	Earnings per share: Basic earnings per share data has been computed on the basis of the weighted average number of common shares outstanding during each period presented.  Diluted earnings per share data has been computed on the basis of the assumed conversion, exercise or issuance of all potential common stock instruments, unless the effect is to reduce the loss or increase the net income per common share (dollars in thousands, except share and per share data):
			Year Ended July 31,
			2014		2013		2012
	Numerator:
	Income from continuing operations		$	3,063	$	2,559	$	5,968
	Loss from discontinued operations net of income tax			--		--		382
	Net income			3,063		2,559		5,586
	Denominator:
	Weighted average common shares and denominator for basic calculation			25,323,622		25,243,010		25,100,064
	Stock options			69,642		94,515		156,520
	Denominator for diluted calculation			25,393,264		25,337,525		25,256,584
	Earnings per share – basic
	Income from continuing operations		$	0.12	$	0.1	$	0.24
	Loss from discontinued operations			--		--		(0.02	)
	Net income		$	0.12	$	0.1	$	0.22
	Earnings per share – diluted
	Income from continuing operations		$	0.12	$	0.1	$	0.24
	Loss from discontinued operations			0		0		(0.02	)
	Net income		$	0.12	$	0.1	$	0.22
	Stock option shares excluded from computation of dilutive income per share because the effect would be antidilutive for the years ended July 31, 2014, 2013 and 2012 were 650,579, 533,079 and 215,734, respectively.
	Segment reporting: Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief decision maker or group in deciding how to allocate resources and in assessing performance.  The Company’s chief decision maker reviews the results of operations and requests for capital expenditures based on one industry segment: producing and selling products and procedures for surgery, primarily for vitreoretinal surgery and neurosurgery.  The Company’s entire revenue is generated through this segment.  Revenues are attributed to countries based upon the location of end-user customers or distributors.
	Reclassifications: Certain reclassifications have been made to the prior year financial statements to conform to the current year’s presentation.

Exit_Costs

Exit Costs	12 Months Ended
	Jul. 31, 2014
Exit Costs [Abstract]	'
Exit Costs	'
	Note 2.  Exit Costs
	On October 1, 2013, the Company announced plans to close its King of Prussia, Pennsylvania facility and consolidate the manufacturing operations into its existing facility in O’Fallon, Missouri. The Company expects to complete the closure by mid-fiscal 2015. Costs are recognized in “Exit costs” in the consolidated statements of income and comprehensive income.  As of July 31, 2014, the Company had a current liability of $112,000 for employee termination benefits in accrued expenses.
		Twelve Months					Cumulative		Total
	(dollars in thousands)	Ended July 31,					as of July 31,		Expected to
		2014			2013		2014		be Incurred
	Employee termination costs	$	615		$	--	$	615	$	1,085
	Other associated costs		67			--		67		79
		$	682		$	--	$	682	$	1,164
		Termination Costs
	Exit liabilities at August 1, 2013	$	--
	Additions		682
	Payments/settlements		(570	)
	Exit liabilities at July 31, 2014	$	112

Acquisitions

Acquisitions	12 Months Ended
	Jul. 31, 2014
Acquisitions [Abstract]	'
Acquisitions	'
	Note 3.  Acquisitions
	On May 3, 2014, the Company acquired a private original equipment manufacturing company incorporated in the United States for net cash consideration of $1.4 million.
	The Company has preliminarily allocated the purchase price to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair value at the date of acquisition resulting in the recognition of $0.8 million of intellectual property and $0.4 million of goodwill, including the impact of deferred income taxes.  The results of operations for the acquired company have been included in the Consolidated Statements of Income from the date of acquisition.
	On July 8, 2013, the Company acquired M.I.S.S. Ophthalmics Limited (“M.I.S.S.”), a private ophthalmology distribution company incorporated in England and Wales, for net cash consideration of $2.8 million.  M.I.S.S. was the Company’s distributor of ophthalmic products in the United Kingdom, and its wholesale distribution activities contributed approximately $1.1 million in revenue to the Company in fiscal 2013.  M.I.S.S. generated total revenue of approximately $3.2 million during its fiscal year ended March 31, 2013.
	The Company allocated the purchase price to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair value at the date of acquisition resulting in the recognition of $0.9 million of intellectual property and $1.5 million of goodwill.  The results of operations for M.I.S.S. have been included in the Consolidated Statements of Income from the date of acquisition.
	No supplemental pro-forma information is presented for the acquisitions due to the immaterial effect of the acquisitions on the Company's financial statements. The Company recognized $64,000 and $70,000 of transaction related costs that were expensed in the years ended July 31, 2014 and 2013, respectively.

Discontinued_Operations

Discontinued Operations	12 Months Ended
	Jul. 31, 2014
Discontinued Operations [Abstract]	'
Discontinued Operations	'
	Note 4.  Discontinued Operations
	In September 2011, the Company adopted a plan to close its plastic injection molding operations and transitioned this production to an outside vendor.  During the Company’s first quarter of fiscal 2012, substantially all operational activities of this unit were discontinued, and the Company classified them as discontinued operations.  The Company completed the sale of these assets prior to the end of the second quarter of fiscal 2012.  The assets included in the disposal group were primarily equipment.  The following table summarizes the results of the discontinued operations fiscal years ended July 31, 2014, 2013 and 2012 (dollars in thousands):
		Year Ended July 31
		2014		2013		2012
	Net sales	$	--	$	--	$	23
	Operating costs		--		--		(191	)
	Impairment, restructuring and other charges		--		--		(253	)
	Write-off of goodwill		--		--		(29	)
	Loss on sale of fixed assets		--		--		(125	)
	Loss from discontinued operations before benefit for income taxes		--		--		(575	)
	Income tax benefit		--		--		193
	Loss from discontinued operations	$	--	$	--	$	(382	)

OEM_Partner_Agreements

OEM Partner Agreements	12 Months Ended
	Jul. 31, 2014
OEM Partner Agreements [Abstract]	'
OEM Partner Agreements	'
	Note 5. OEM Partner Agreements
	The Company sells all of its generators and a majority of its neurosurgery instruments and accessories to two U.S. based national and international OEM partners as described below:
	Codman
	In the neurosurgical market, the bipolar electrosurgical system manufactured by Valley Forge prior to the merger has been sold for over 30 years through a series of distribution agreements with Codman, an affiliate of Johnson & Johnson.  On April 2, 2009, the Company executed a new, three-year distribution agreement with Codman for the continued distribution by Codman of certain bipolar generators and related disposables and accessories, effective January 1, 2009.  In addition, the Company entered into a new, three-year license agreement, which provides for the continued licensing of the Company’s Malis® trademark to Codman for use with certain Codman products, including those covered by the distribution agreement.  Both agreements expired on December 31, 2011 and have renewed for three years.  In December 2010, Codman elected to exercise its option of exclusive distribution with respect to the bipolar generators and related disposables and accessories.
	On November 16, 2009, the Company announced the signing of an addendum to its three-year agreement with Codman.  Under the terms of the revised agreement, Codman has the exclusive right to market and distribute the Company’s Malis® branded disposable bipolar forceps produced by Synergetics.  Codman began distribution of the disposable bipolar forceps on December 1, 2009, domestically, and on February 1, 2010, internationally.
	Total sales to Codman and its respective percent of the Company’s net sales for the years ended July 31, 2014, 2013 and 2012, including the historical sales of generators, accessories and disposable cord tubing that the Company has supplied in the past, as well as the disposable bipolar forceps sales resulting from the addendum to the existing distribution agreement, were as follows (dollars in thousands):
		Year Ended July 31,
		2014			2013			2012
	Net sales	$	15,173		$	14,097		$	11,150
	Percent of net sales		23.4	%		22.4	%		18.6	%
	Stryker Corporation (“Stryker”)
	The Company supplies a multi-channel ablation generator, used for minimally invasive pain treatment, to Stryker pursuant to a supply and distribution agreement dated as of October 25, 2004, as amended.  The agreement expires on June 30, 2015.
	On March 31, 2010, the Company entered into a supply agreement with Stryker pursuant to which the Company agreed to supply Stryker with disposable ultrasonic aspirator instrument tips and certain other consumable products used in conjunction with Stryker’s ultrasonic aspirator console and handpieces.  The agreement expires on March 31, 2016.
	Total sales to Stryker and its respective percent of the Company’s net sales for the years ended July 31, 2014, 2013 and 2012, including the historical sales of pain control generators, and accessories that the Company has supplied in the past, as well as the disposable ultrasonic aspirator instrument tips sales and certain other consumable products resulting from the new agreements, were as follows (dollars in thousands):
		Year Ended July 31,
		2014			2013			2012
	Net sales	$	10,779		$	10,815		$	10,398
	Percent of net sales		16.6	%		17.2	%		17.3	%
	No other customer comprises more than 10 percent of sales in any given year.

Inventories

Inventories	12 Months Ended
	Jul. 31, 2014
Inventories [Abstract]	'
Inventories	'
	Note 6. Inventories
	Inventories as of July 31, 2014 and 2013 were as follows (dollars in thousands):
		2014		2013
	Raw material and component parts	$	5,900	$	7,418
	Work in progress		2,077		1,133
	Finished goods		7,157		6,274
		$	15,134	$	14,825

Property_and_Equipment

Property and Equipment	12 Months Ended
	Jul. 31, 2014
Property and equipment [Abstract]	'
Property and Equipment	'
	Note 7.  Property and Equipment
	Property and equipment as of July 31, 2014 and 2013 were as follows (dollars in thousands):
		2014		2013
	Land	$	984	$	730
	Building and improvements		6,650		6,365
	Machinery and equipment		9,023		8,665
	Furniture and fixtures		1,182		1,058
	Software		1,113		1,107
	Construction in progress		153		177
			19,105		18,102
	Less accumulated depreciation		10,320		9,140
		$	8,785	$	8,962
	Depreciation expense is included in both cost of sales, selling and general and administrative expenses.  There are minimal long-lived assets outside of the United States.  Depreciation expense for the years ended July 31, 2014, 2013 and 2012 was approximately $1.2 million, $1.1 million and $1.1 million, respectively.

Other_Intangible_Assets

Other Intangible Assets	12 Months Ended
	Jul. 31, 2014
Other Intangible Assets [Abstract]	'
Other Intangible Assets	'
	Note 8.  Other Intangible Assets
	Information regarding the Company’s other intangible assets is as follows (dollars in thousands):
		Gross Carrying		Accumulated		Net
		Value		Amortization
		31-Jul-14
	Proprietary know-how	$	4,208	$	2,208	$	2,000
	Trademark		5,944		--		5,944
	Licensing agreement		5,694		2,895		2,799
	Other intangibles		1,279		111		1,168
	Patents		2,375		903		1,472
		$	19,500	$	6,117	$	13,383
		31-Jul-13
	Proprietary know-how	$	3,707	$	1,936	$	1,771
	Trademark		5,938		--		5,938
	Licensing agreement		5,694		2,626		3,068
	Other intangibles		938		--		938
	Patents		2,087		676		1,411
		$	18,364	$	5,238	$	13,126
	Goodwill of $439,000 and other intangibles of $765,000 are a result of the acquisition of the private ophthalmic manufacturing company completed on May 3, 2014.  Goodwill of $1.5 million and other intangibles of $0.9 million are a result of the acquisition of M.I.S.S completed on July 8, 2013.  Goodwill of $10.7 million and proprietary know-how of $3.7 million are a result of the reverse merger transaction completed on September 21, 2005.  The Company did not incur costs to renew or extend the term of acquired intangible assets during the fiscal year ended July 31, 2014.
	Amortization is included in general and administrative expense and was $876,000, $680,000 and $600,000 for the years ended July 31, 2014, 2013 and 2012, respectively.  Amortization for the next five years is expected to approximate $975,000 annually.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Jul. 31, 2014
Accrued Expenses [Abstract]	'
Accrued Expenses	'
	Note 9. Accrued Expenses
	Accrued expenses as of July 31, 2014 and 2013 consisted of the following (dollars in thousands):
		2014		2013
	Payroll, commissions and employee benefits	$	1,402	$	1,737
	Operations/services		832		1,421
	Taxes other than income		611		328
		$	2,845	$	3,486

Pledged_Assets_Short_and_LongT

Pledged Assets, Short and Long-Term Debt	12 Months Ended
	Jul. 31, 2014
Pledged Assets, Short and Long-Term Debt [Abstract]	'
Pledged Assets, Short and Long-Term Debt	'
	Note 10.  Pledged Assets, Short and Long-Term Debt
	Revolving Credit Facility: The Company has a credit facility with a bank which allows for borrowings of up to $9.5 million with an interest rate based on either the one-, two- or three-month LIBOR plus 1.75 percent and adjusting each quarter based upon our leverage ratio. As of July 31, 2014, interest under the facility is charged at 1.98 percent. The unused portion of the facility is charged at a rate of 0.20 percent. There were no borrowings under this facility at July 31, 2014. Outstanding amounts are collateralized by the Company’s domestic receivables and inventory. This credit facility was amended on September 30, 2013, to extend the termination date through September 30, 2016.
	The facility has two financial covenants: a maximum leverage ratio of 2.25 times and a minimum fixed charge coverage ratio of 1.25 times. As of July 31, 2014, the Company’s leverage ratio was zero, as there is no outstanding debt as of July 31, 2014, and the minimum fixed charge coverage ratio was 352 times, as interest expense was minimal. The facility restricts the payment of dividends if, following the distribution, the fixed charge coverage ratio would fall below the required minimum.
	Equipment Line of Credit: Under this credit facility, the Company may borrow up to $1.0 million, with interest currently at one-month LIBOR plus 3.0 percent. Pursuant to the terms of the equipment line of credit, under no circumstance shall the rate be less than 3.5 percent per annum. The unused portion of the facility is not charged a fee. There were no borrowings under this line as of July 31, 2014. The equipment line of credit was amended on September 30, 2013 to extend the maturity date to September 30, 2016.

Operating_Leases

Operating Leases	12 Months Ended
	Jul. 31, 2014
Operating Leases [Abstract]	'
Operating Leases	'
	Note 11. Operating Leases
	The Company leases various equipment, a portion of its facilities in O’Fallon, Missouri, the facility in California and the facility in King of Prussia, Pennsylvania under operating leases.  The O’Fallon, Missouri lease expires in February 2016, the California lease expires in November 2017 and the King of Prussia, Pennsylvania lease expires in October 2015.
	The approximate minimum rental commitment under non-cancelable operating leases as of July 31, 2014 is due as follows (dollars in thousands):
	Year Ending July 31,	Amount
	2015	$	394
	2016		173
	2017		75
	2018		26
	2019		--
		$	668
	Rent expense incurred and charged to cost of sales and selling, general and administrative expenses was approximately $457,000, $364,000 and $353,000 for the years ended July 31, 2014, 2013 and 2012, respectively.

Income_Tax_Matters

Income Tax Matters	12 Months Ended
	Jul. 31, 2014
Income Tax Matters [Abstract]	'
Income Tax Matters	'
	Note 12. Income Tax Matters
	The Company and its wholly owned subsidiaries file as a single entity for income tax reporting purposes.  The net deferred income tax amounts included in the accompanying consolidated balance sheets as of July 31, 2014 and 2013 include the following amounts as deferred income tax assets and liabilities (dollars in thousands):
		2014			2013
	Deferred tax assets:
	Accounts receivable	$	204		$	119
	Inventories		1,002			847
	Accrued liabilities		173			186
	Deferred revenue		5,456			5,940
	Other		172			133
	Loss on foreign subsidiaries		1,720			2,080
	Valuation allowance		(1,720	)		--
			7,007			9,305
	Deferred tax liability
	Property and equipment		960			1,561
	Other intangible assets		2,786			2,360
			3,746			3,921
		$	3,261		$	5,384
	The Company recorded a valuation allowance of the losses of its foreign subsidiaries in conjunction with its overall income tax strategy including the inclusion of its foreign losses on its U.S. tax return.
	The deferred tax amounts noted above have been classified on the accompanying consolidated balance sheets as of July 31, 2014 and 2013, as follows (dollars in thousands):
		2014			2013
	Current assets	$	2,042		$	1,827
	Long-term asset		1,219			3,557
		$	3,261		$	5,384
	The provision for income taxes for the years ended July 31, 2014, 2013 and 2012, consisted of the following (dollars in thousands):
		2014			2013			2012
	Current (receivable) payable	$	(338	)	$	1,179		$	2,153
	Deferred		1,836			(49	)		153
		$	1,498		$	1,130		$	2,306
	Reconciliation of the Company’s income tax at the statutory rate to the Company’s effective rate is as follows:
		2014			2013			2012
	Computed at the statutory rate		34	%		34	%		34	%
	State taxes, net of federal tax benefit		2.4			2.5			2.4
	Foreign rate differential		(3.2	)		--			--
	Production deduction for domestic manufacturers		(2.0	)		(4.3	)		(2.9	)
	Research and experimentation		(1.6	)		(5.3	)		(0.8	)
	Other		3.2			3.7			(3.2	)
			32.8	%		30.6	%		29.5	%

Employee_Benefit_Plan

Employee Benefit Plan	12 Months Ended
	Jul. 31, 2014
Employee Benefit Plan [Abstract]	'
Employee Benefit Plan	'
	Note 13. Employee Benefit Plan
	The Company has a 401(k) savings plan, which covers employees who have attained the age of 18 and who have been credited with at least one year of service.  Company contributions are made at the discretion of the Board of Directors.  The Company contributed $120,000, $203,000 and $79,000 to the plan for the years ended July 31, 2014, 2013 and 2012.

StockBased_Compensation_Plans

Stock-Based Compensation Plans	12 Months Ended
	Jul. 31, 2014
Stock-Based Compensation Plans [Abstract]	'
Stock-Based Compensation Plans	'
	Note 14. Stock-Based Compensation Plans
	Stock Option Plans
	In addition to the historical options outstanding for Synergetics prior to the merger, the Company has options outstanding under two existing active option plans and two terminated plans of Valley Forge.  Under the Amended and Restated Synergetics USA, Inc. 2001 Stock Plan (the “2001 Plan”), 2,000,000 shares of common stock are authorized for issuance to employees, officers and consultants of the Company.  There were 629,484 options and restricted shares not yet awarded at July 31, 2014 under the 2001 Plan.  Pursuant to the Amended and Restated Synergetics USA, Inc. 2005 Non-Employee Directors’ Stock Option Plan, as amended (the “Non-Employee Directors’ Stock Option Plan”), 700,000 shares of common stock are authorized for issuance to non-employee directors.  There were 285,000 options available for future grants at July 31, 2014 under the Non-Employee Directors’ Stock Option Plan.  Generally, options are granted with an exercise price equal to market value at the date of grant and expire ten years from the date of the grant.  Generally, stock options granted under these plans vest over a three to five-year period, with the exception of the non-employee director options, which vest over a 12-month period.
	A summary of the status of the fixed awards at July 31, 2014, 2013 and 2012 and changes during the years ended on those dates is as follows:
		Shares			Weighted				Weighted
					Average				Average Fair
					Exercise				Value
					Price
	Options outstanding, July 31, 2011		517,029		$	2.68			$	2.16
	Granted		235,734		$	6.21			$	4.75
	Forfeited		(56,133	)	$	4.11			$	3.22
	Exercised		(16,885	)	$	2.07			$	1.99
	Options outstanding, July 31, 2012		679,745		$	3.8			$	2.98
	Granted		142,227		$	4.52			$	3.42
	Forfeited		(15,000	)	$	4.54			$	3.66
	Exercised		(59,310	)	$	1.1			$	0.95
	Options outstanding, July 31, 2013		747,662		$	3.23			$	4.17
	Granted		117,500		$	3.64			$	2.72
	Forfeited		--			--				--
	Exercised		(50,000	)	$	1.17			$	0.97
	Options outstanding July 31, 2014		815,162		$	4.25			$	3.27
	Options exercisable, July 31, 2014		582,299		$	4.1			$	3.18
	A further summary of the awards outstanding at July 31, 2014 is as follows:
		Shares			Weighted Average
					Grant Date Value
	Unvested options, beginning of period		233,211		$	3.84
	Granted		117,500		$	2.72
	Vested		(117,848	)	$	3.4
	Forfeited		--			--
	Unvested options, period end		232,863		$	3.5
	Proceeds, related tax benefits realized from options exercised and the intrinsic value of options exercised were as follows (dollars in thousands), except exercise price:
		Fiscal Year Ended
		31-Jul-14			31-Jul-13				31-Jul-12
	Proceeds of options exercised	$	59		$	65			$	35
	Related tax benefit recognized		38			72				24
	Intrinsic value of options exercised		48			56				34
	The following table provides information about options outstanding and exercisable options at July 31, 2014 (dollars in thousands):
		Options			Exercisable
		Outstanding			Options
	Number		815,162			582,299
	Weighted average exercise price	$	4.25		$	4.1
	Aggregate intrinsic value	$	3,464		$	2,387
	Weighted average contractual term	6.5 years			5.8 years
	The weighted average remaining life for options outstanding and weighted average exercise price per share for exercisable options at July 31, 2014 were as follows:
			Options Outstanding				Exercisable Options
			Shares		Weighted Average		Shares			Weighted Average
					Remaining					Remaining
					Contractual Life (in					Contractual Life (in
					years)					years)
	<$ 2.00			124,583	5.0 years			117,583		5.0 years
	$ 2.01 to $3.00			40,000	3.3 years			40,000		3.3 years
	$ 3.01 to $4.00			157,500	7.6 years			64,792		5.1 years
	$ 4.01 to $5.00			257,345	6.8 years			196,800		6.5 years
	$ 5.01 to $6.21			235,734	6.8 years			163,124		6.6 years
	Total			815,162	6.5 years			582,299		5.8 years
	During the second quarter of fiscal 2014, there were options to purchase 60,000 shares of common stock granted to the Company’s independent directors, which vest pro-ratably on a quarterly basis over the next year of service.  Each independent director receives an option to purchase 10,000 shares of the Company’s common stock each year in which he or she is elected, appointed, or re-elected to serve, or continues to serve as a director pursuant to the Non-Employee Directors’ Stock Option Plan. These options vest pro-ratably on a quarterly basis over the next year of service on the Board.
	During the second quarter of fiscal 2014, there were options to purchase 57,500 shares of common stock granted to the officers of the Company.  These options were granted in conjunction with the Company’s annual review of compensation as of August 1, 2013 and vest on a quarterly basis over the next four years of service. The Company recorded $24,000 of compensation expense for the fiscal year ended July 31, 2014, related to these options.
	The Company expects to issue new shares as options are exercised. As of July 31, 2014, the future compensation cost expected to be recognized for currently outstanding stock options is approximately $324,000 in fiscal 2015, $238,000 in fiscal 2016, $119,000 in fiscal 2017 and $17,000 in fiscal 2018.
	The following table provides the assumptions used in the Black-Scholes model:
		Fiscal Year Ended July 31,
		2014			2013				2012
	Expected average risk-free interest rate		2.9	%		1.72	%			1.92	%
	Expected average life (in years)		10			10				10
Expected volatility		68.6	%		70.5	%			71.4	%
Expected dividend yield		0	%		0	%			0	%
The expected average risk-free rate is based on 10-year U.S. treasury yield curve in December of 2013.  The expected average life represents the period of time that options granted are expected to be outstanding giving consideration to vesting schedules, historical exercise and forfeiture patterns.  Expected volatility is based on historical volatilities of Synergetics USA, Inc.’s common stock.  The expected dividend yield is based on historical information and management’s plan.
Restricted Stock Plans
Under the Company’s 2001 Plan, the Company’s common stock may be granted at no cost to certain employees and consultants of the Company.  Certain plan participants are entitled to cash dividends and voting rights for their respective shares.  Restrictions limit the sale or transfer of these shares during a vesting period whereby the restrictions lapse either pro-ratably over a three-year or five-year vesting period or at the end of the third or fifth year.  These shares also vest upon a change of control event.  Upon issuance of stock under the 2001 Plan, unearned compensation equivalent to the market value at the date of the grant is charged to stockholders’ equity and subsequently amortized to expense over the applicable restriction period.  As of July 31, 2014, there was approximately $580,000 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Company’s 2001 Plan.  The cost is expected to be recognized over a weighted average period of four years which is generally the vesting period.
In addition, during the fiscal year ended July 31, 2014, 14,648 shares were granted to advisory consultants under the 2001 Plan.  Compensation expense related to these shares was $55,000 for the fiscal year ended July 31, 2014.
The following table provides information about restricted stock awards during the fiscal year ended July 31, 2014, 2013 and 2012:
	Number of Shares			Weighted Average
				Grant Date Fair Value
Balance as of August 1, 2011		310,707		$	2.38
Granted		202,072			6.37
Forfeited		(39,384	)		5.88
Vested		(41,617	)		3.47
Balance as of July 31, 2012		431,778			3.82
Granted		70,307			4.52
Forfeited		(10,160	)		3.47
Vested		(86,677	)		4.57
Balance as of July 31, 2013		405,248			3.79
Granted		7,000			3.38
Forfeited		(2,335	)		3.88
Vested		(134,366	)		4.52
Balance as of July 31, 2014		275,547			3.42
Compensation expense associated with stock-based compensation plans as of July 31, 2014, 2013 and 2012 was as follows (dollars in thousands):
	31-Jul-14			31-Jul-13				31-Jul-12
Stock Options:
Directors	$	163		$	230			$	217
Employees		364			233				154
Total	$	527		$	463			$	371
Restricted Stock
Employees	$	426		$	413			$	357
Advisors		55			55				36
Total		481			468				393
Total Compensation Expense	$	1,008		$	931			$	764
Income Tax benefits from Share-based Compensation	$	331		$	285			$	225
As a result of the King of Prussia facility closure and resulting acceleration of vesting of stock compensation, $201,000 of this compensation expense is included in Exit Costs for the fiscal year ended July 31, 2014.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Jul. 31, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	Note 15.  Stockholders’ Equity
	Upon completion of the reverse merger between Valley Forge and Synergetics on September 22, 2005, the Company reincorporated in Delaware, decreased the par value of common stock from $0.01 2/3 to $0.001, increased the authorized common shares to 50,000,000 and eliminated the outstanding treasury shares.
	The holders of common stock have no preemptive rights and the common stock has no redemption, sinking fund or conversion provisions.  Each share of common stock is entitled to one vote on any matter submitted to the holders and to equal rights in the assets of the Company upon liquidation.  All of the outstanding shares of common stock are fully paid and nonassessable.

Research_and_Development_Costs

Research and Development Costs	12 Months Ended
	Jul. 31, 2014
Research and Development Costs [Abstract]	'
Research and Development Costs	'
	Note 16. Research and Development Costs
	R&D costs related to both future and present products are charged to operations as incurred.  The Company incurred approximately $5.2 million, $3.6 million and $3.6 million of R&D costs during the years ended July 31, 2014, 2013 and 2012, respectively.

Enterprisewide_Sales_Informati

Enterprise-wide Sales Information	12 Months Ended
	Jul. 31, 2014
Enterprise-wide Sales Information [Abstract]	'
Enterprise-wide Sales Information	'
	Note 17. Enterprise-wide Sales Information
	Enterprise-wide sales information as of July 31, 2014, 2013 and 2012 consisted of the following (dollars in thousands):
			Fiscal Year Ended July 31,
			2014		2013		2012
	Net Sales
	Ophthalmic		$	35,242	$	35,446	$	35,240
	OEM (1)			28,671		26,469		23,973
	Other (2)			856		881		801
	Total		$	64,769	$	62,796	$	60,014
			Fiscal Year Ended July 31,
			2014		2013		2012
	Net Sales
	Domestic		$	48,407	$	46,489	$	44,047
	International			16,362		16,307		15,967
	Total		$	64,769	$	62,796	$	60,014
		-1	Net sales from OEM represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel generators, disposable ultrasonic tips and related accessories to Stryker, and sales of certain disposable products. Recognition of deferred revenues of $1.3 million from Alcon is included in this category for the fiscal years ended July 31, 2014 and 2013, and recognition of deferred revenues of $266,000 and $1.2 million from Codman and Alcon, respectively, are included in this category for the fiscal year ended July 31, 2012.
		-2	Net sales from Other represent direct neurosurgery revenues and other miscellaneous revenues.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Jul. 31, 2014
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies	'
	Note 18. Commitments and Contingencies
	The Company has entered into change of control agreements with each of its President and Chief Executive Officer, Chief Financial Officer, Vice President of Domestic Sales and Vice President of Marketing and Technology.  The change in control agreements with its executive officers provide that if employment is terminated within one year for cause or disability following a change in control (as each term is defined in the change in control agreements), as a result of the officers’ death, or by the officer other than as an involuntary termination (as defined in the change in control agreements), the Company shall pay the officer all compensation earned or accrued through his or her employment termination date, including (i) base salary; (ii) reimbursement for reasonable and necessary expenses; (iii) vacation pay; (iv) bonuses and incentive compensation; and (v) all other amounts to which they are entitled under any compensation or benefit plan of the Company (“Standard Compensation Due”).
	If the officer’s employment is terminated within one year following a change in control without cause and for any reason other than death or disability, including an involuntary termination, and provided the officer enters into a separation agreement within 30 days of his or her employment termination, he or she  shall receive the following: (i) all Standard Compensation Due and any amount payable as of the termination date under the Company’s objectives-based incentive plan, the sum of which shall be paid in a lump sum immediately upon such termination; and (ii) an amount equal to one times his or her annual base salary at the rate in effect immediately prior to the change in control, to be paid in 12 equal monthly installments beginning in the month following his or her employment termination. Furthermore, all of the officer’s awards of shares or options shall immediately vest and be exercisable for one year after the date of his or her employment termination.
	Various claims, incidental to the ordinary course of business, are pending against the Company.  In the opinion of management, after consultation with legal counsel, resolution of these matters is not expected to have a material effect on the accompanying financial statements.
	The Company is subject to regulatory requirements throughout the world. In the normal course of business, regulatory agencies may require companies in the medical industry to change their products or operating procedures, which could affect the Company.  The Company regularly incurs expenses to comply with these regulations and may be required to incur additional expenses.  Management is not able to estimate any additional expenditures outside the normal course of operations which will be incurred by the Company in future periods in order to comply with these regulations.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Jul. 31, 2014
Quarterly Financial Data (Unaudited) [Abstract]	'
Quarterly Financial Data (Unaudited)	'
	Note 19. Quarterly Financial Data (Unaudited)
	The following table provides the Company’s quarterly information as presented in the Form 10-Q (dollars in thousands except share and per share data):
	Quarters ended:	July 31,		April 30,		January 31,			October 31,
		2014*		2014		2014			2013
	Net sales	$	18,008	$	16,135	$	15,096		$	15,530
	Gross profit		9,995		8,912		8,398			8,924
	Operating income		2,156		1,411		(377	)		1,391
	Net income		1,410		943		(225	)		935
	Earnings per share - basic	$	0.06	$	0.04	$	(0.01	)	$	0.04
	Earnings per share - diluted	$	0.06	$	0.04	$	(0.01	)	$	0.04
	Basic weighted average common shares outstanding		25,352,326		25,331,925		25,309,641			25,294,020
	Diluted weighted average common shares outstanding		25,400,341		25,392,782		25,309,641			25,389,940
	Quarters ended:	July 31,		April 30,		January 31,			October 31,
		2013**		2013		2013			2012
	Net sales	$	17,857	$	16,264	$	14,055		$	14,620
	Gross profit		9,676		9,051		5,171	***		8,473
	Operating income		2,212		1,721		(2,153	)		1,941
	Net income		1,439		1,150		(1,382	)		1,352
	Earnings per share – basic	$	0.06	$	0.05	$	(0.05	)	$	0.05
	Earnings per share – diluted	$	0.06	$	0.05	$	(0.05	)	$	0.05
	Basic weighted average common shares outstanding		25,290,882		25,299,131		25,230,142			25,160,757
	Diluted weighted average common shares outstanding		25,367,558		25,362,923		25,230,142			25,286,184
	*        The acquisition of the private OEM company has been reflected in our results of operations from May 3, 2014, the date of the acquisition.
	**      The M.I.S.S. acquisition has been reflected in our results of operations from July 8, 2013, the date of the acquisition.
	***    In the second quarter of fiscal 2013, the Company recorded an inventory write-down of approximately $2.1 million, or approximately $0.06 per share, net of tax.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	12 Months Ended
	Jul. 31, 2014
Recent Accounting Pronouncements [Abstract]	'
Recent Accounting Pronouncements	'
	Note 20. Recent Accounting Pronouncements
	In March 2013, the Financial Accounting Standards Board (“FASB”) issued an accounting standard update requiring an entity to release into net income the entire amount of a cumulative translation adjustment related to its investment in a foreign entity when as a parent it either sells a part or all of its investment in the foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets within the foreign entity. This accounting standard update is effective for the Company as of the first quarter of fiscal 2015. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements.
	In July 2013, the FASB issued an accounting standard update that provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward or a tax credit carryforward exists. Under the new standard update, unrecognized tax benefit, or a portion of an unrecognized tax benefit, is to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward or a tax credit carryforward. This accounting standard update will be effective for the Company beginning in the first quarter fiscal 2015 and applied prospectively with early adoption permitted. The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements.
	In April 2014, the FASB issued an accounting standard update increasing the threshold for a disposal to qualify as a discontinued operation and require new disclosures of both discontinued operations and certain other disposals that do not meet the definition of a discontinued operation.  The standard will be effective for the Company beginning in the second quarter fiscal 2015.  The adoption of the pronouncement may affect the Company’s presentation of future dispositions.
	In May 2014, the FASB issued an accounting standard update that provides explicit guidance on the recognition of revenue based upon the entity’s contracts with customers to transfer goods or services.  Under the new standard update, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.  This accounting standard update will be effective for the Company in the first quarter of fiscal 2018.  The Company is currently evaluating the impact of this accounting standard update on its consolidated financial statements.
	In June 2014, the FASB issued an accounting standard update that provides explicit guidance on whether there is substantial doubt about an entity’s ability to continue as a going concern.  Before the issuance of this update, there was no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. This guidance is expected to reduce the diversity in the timing and content of footnote disclosures. The guidance requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards as specified in the guidance. The guidance becomes effective for the annual period ending after December 15, 2016 and for annual and interim periods thereafter. Early adoption is permitted. The Company is currently evaluating the effects of adopting this guidance on its consolidated financial statements but the adoption is not expected to have a significant impact on the Company’s consolidated financial statements.
	The Company has reviewed all other recently issued, but not yet effective, accounting pronouncements and does not believe any such pronouncements will have a material impact on its financial statements.

Valuation_Allowances_and_Quali

Valuation Allowances and Qualifying Accounts	12 Months Ended
	Jul. 31, 2014
Valuation Allowances and Qualifying Accounts [Abstract]	'
Valuation Allowances and Qualifying Accounts	'
	Note 21. Valuation Allowances and Qualifying Accounts
	Schedule II — Valuation Allowances and Qualifying Accounts
	(dollars in thousands)
	Classifications	Balance at		Charges to		Charges to		Deduction		Balance at
		Beginning		Cost and		Other		from		End of
		of Year		Expenses		Accounts		Reserves		Year
	Year ended July 31, 2012
	Allowance for Doubtful Accounts & Returned Goods	$	282	$	37	$	--	$	--	$	319
	Allowance for Excess and Obsolete Inventory	$	82	$	384	$	--	$	--	$	466
	Year ended July 31, 2013
	Allowance for Doubtful Accounts & Returned Goods	$	319	$	207	$	--	$	31	$	495
	Allowance for Excess and Obsolete Inventory	$	466	$	1,368	$	--	$	--	$	1,834
	Year ended July 31, 2014
	Allowance for Doubtful Accounts & Returned Goods	$	495	$	338	$	--	$	111	$	722
	Allowance for Excess and Obsolete Inventory	$	1,834	$	383	$	--	$	--	$	2,217

Nature_of_Business_and_Signifi1

Nature of Business and Significant Accounting Policies (Policies)	12 Months Ended
	Jul. 31, 2014
Nature of Business and Significant Accounting Policies [Abstract]	'
Use of estimates in the preparation of financial statements	'
	Use of estimates in the preparation of financial statements: The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.
Principles of consolidation	'
	Principles of consolidation: The consolidated financial statements include the accounts of Synergetics USA and its wholly owned subsidiaries: Synergetics, Synergetics IP, Inc., Synergetics Development Company, LLC and Synergetics Delaware, Inc.  All significant intercompany accounts and transactions have been eliminated.
Cash and cash equivalents	'
	Cash and cash equivalents: For purposes of the consolidated statements of cash flows, the Company considers all highly liquid debt instruments purchased with maturity of three months or less to be cash equivalents.
Accounts receivable	'
	Accounts receivable: During the ordinary course of its business, the Company grants unsecured credit to its domestic and international customers.  Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis.  Collateral is not generally required on the Company’s accounts receivable.  Accounts receivable are generally considered past due based upon their specific terms.  Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions.  Accounts receivable are written off when deemed uncollectible.  Recoveries of accounts receivable previously written off are recorded when received.  The Company generally does not charge interest on past-due amounts in accounts receivable.  The Company has a history of minimal uncollectible accounts.
Concentration of credit risk	'
	Concentration of credit risk: Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and accounts receivable.  The Company’s cash and cash equivalents are primarily held in a money market account in a bank and currently exceed the FDIC insurance limit.  Generally these deposits can be redeemed upon demand and therefore, bear minimal risk.
Inventories	'
	Inventories: Inventories, consisting of purchased materials, direct labor and manufacturing overhead, are stated at the lower of cost or market, with cost being determined using the first-in, first-out method. The Company’s inventory is very dynamic and new products are added frequently.  Thus, the Company reviews the valuation of its inventory on a quarterly basis and determines if a valuation allowance is necessary for items, including any excess quantities and identified obsolescence.  The Company monitors inventory activity by product type and uses both quantitative and qualitative factors to access the need for a reserve. The inventory analysis takes into account historical experience, the inventory’s length of time on hand, historical sales, product life cycle and product obsolescence. To the extent that the Company determines there are some excess quantities based on its projected levels of sales and other requirements, or obsolete material in inventory, the Company records a valuation reserve against all or a portion of the value of the related parts or products. If future cost valuations, future demand or market conditions are different from the Company’s projections, a change in recorded inventory reserve may be required and would be reflected in cost of sales in the period the revision is made.
	During the second quarter of fiscal 2013, the Company completed a detailed analysis of its inventory and recorded a reserve for excess inventory of approximately $1.6 million.  In its continuous effort to manage its inventory, the Company had previously conducted an inventory analysis of obsolete inventory and recorded a provision for same in the third quarter of fiscal 2012.   The reserve was necessary to reflect not only the Company’s changing base ophthalmic business but also to reflect the appropriate level and mix identified in accordance with the Company’s continuous improvement methodology with respect to its inventory.
Property and equipment	'
	Property and equipment: Property and equipment are depreciated using the straight-line method over their estimated useful lives as follows:
		Useful lives (in years)
	Building and improvements	Jul-39
	Machinery and equipment	7-May
	Furniture and fixtures	7-May
	Software	10-Mar
Goodwill and other intangibles	'
	Goodwill and other intangibles: Absent any impairment indicators, goodwill is tested for impairment on an annual basis.  The Company performs its goodwill impairment tests during the fourth fiscal quarter.  The Company has adopted the provisions of Accounting Standards Update (“ASU”) No. 2011-08, “Intangibles – Goodwill and Other:  Testing Goodwill for Impairment” and ASU No. 2012-12, “Intangibles – Goodwill and Other:  Testing Indefinite-Lived Intangible Assets for Impairment,” which permits the Company to assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that goodwill and other intangibles have been impaired.  The Company has determined, based upon an assessment of qualitative factors, that it is more likely than not that goodwill and other intangibles have not been impaired and no further testing was performed as of July 31, 2014.  Other intangible assets, consisting of licensing agreements, proprietary know-how and customer relationships, are amortized to operations under the straight-line method over their estimated useful lives or statutory lives, whichever is shorter.  These periods range from three to fifteen years.  The life of a trademark is inextricably related to the life of the product bearing the mark or the life of the business entity owning the trademark.  The Company intends to use the Malis® trademark indefinitely, and therefore, its useful life is not limited to any specific product. The trademark constitutes an indefinite-lived intangible that will be used in perpetuity.  Proprietary know-how consists of the patented technology which is included in the Company’s core product lines, bipolar electrosurgical generators. The Company also recorded intangible assets related to proprietary know-how and customer relationships in relation to its two recent acquisitions. Proprietary technology and expertise are distinguishing features of the Company’s products and represent a valuable intangible asset.
Patents	'
	Patents: Incremental legal and other costs to obtain the patent are capitalized to a patent asset.  Salaries, benefits and other direct costs of product development are expensed as operating expenses in research and development (“R&D”) costs.  Patents are amortized to operations under the straight-line method over the remaining statutory life of the patent.
Deferred revenue	'
	Deferred revenue: During the second quarter of fiscal 2011, the Company received a payment from Codman & Shurtleff, Inc. (“Codman”), an original equipment manufacturer (“OEM”) partner, to establish exclusivity on certain generator products and accessories.  Revenue from the agreement has been deferred and is being amortized over its expected term.  The Company recognized $0, $0 and $266,000 in revenue for the fiscal years ended July 31, 2014, 2013 and 2012, respectively, under the terms of the exclusivity agreement.
	On April 23, 2010, the Company entered into a Settlement and License Agreement with Alcon, Inc. (“Alcon”)  pursuant to which Alcon paid to the Company $32.0 million. The net proceeds to the Company were $21.4 million after contingency payments to attorneys. The Company recognized a gain from this agreement of $2.4 million in the third quarter of fiscal 2010. The remaining $19.0 million has been accounted for as an up-front license fee under the Confidential Settlement and License Agreement and was deferred and recognized as earned over a period estimated to be 15 years based upon estimated shipments to Alcon under a related Supply Agreement.  On February 13, 2012, Alcon informed the Company that it had decided to cancel the project, orders and forecasts covering the two products to have been supplied under the Supply Agreement. However, the Supply Agreement remains in effect and the Company has continuing performance obligations associated with the Supply Agreement. Therefore, the Company plans to recognize the remaining deferred revenue associated with the Supply Agreement ratably over the next 12 years which is the remaining life of the patents and associated Supply Agreement. The Company recognized $1.3 million, $1.3 million and $1.2 million of this deferred revenue for the fiscal years ended July 31, 2014, 2013 and 2012, respectively.
			31-Jul-14		31-Jul-13
	Deferred revenue – Alcon settlement		$	14,530	$	15,818
	Less:  Short-term			1,288		1,288
	Long-term portion		$	13,242	$	14,530
Impairment of long-lived assets (excluding goodwill and other intangibles)	'
	Impairment of long-lived assets (excluding goodwill and other intangibles): The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted cash flows expected to be generated by the asset.  Measurement of an impairment loss for long-lived assets and certain identifiable assets that management expects to hold and use is based on the fair value of the asset.  Assets to be sold are reported at the lower of the carrying amount or the fair value less costs to sell.
Product warranty	'
	Product warranty: The Company provides a warranty against manufacturing and workmanship defects. Under the Company’s general terms and conditions of sale, liability during the warranty period (typically three years) is limited to repair or replacement of the defective item. The Company’s warranty cost is not material.
Income taxes	'
	Income taxes: The Company accounts for income taxes under Accounting Standards Codification Topic 740, “Income Taxes” (“ASC Topic 740”).  Under ASC Topic 740, the deferred tax provision is determined using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss, tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences.  Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases.  Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.  Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
	In addition, under ASC Topic 740, the Company may recognize tax liabilities when, despite the Company’s belief that its tax return positions are supported, the Company believes that certain positions may not be fully sustained upon review by tax authorities.  The Company has identified no uncertain tax positions subsequent to the adoption of this standard on August 1, 2007.
	The Company’s policy is to recognize interest and penalties through income tax expense.  As of July 31, 2014, the 2011 to 2013 tax years remain subject to examination by major tax jurisdictions.  There are no federal income tax audits in process as of July 31, 2014. There is one state audit currently in progress.
Fair value of financial instruments	'
	Fair value of financial instruments: The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses.  As of July 31, 2014, and 2013, the carrying amounts of financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate fair value due to the short maturity of these instruments.
	Non-financial assets such as goodwill, intangible assets and property, plant and equipment are measured at fair value when there is an indicator of impairment and recorded at fair value only when impairment is recognized.  No impairment indicators existed as of July 31, 2014.
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).  The fair value hierarchy consists of these broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).  The Company’s Level 1 financial assets are money market funds, whose fair values are based on quoted market prices. The Company does not have any Level 2 or Level 3 financial assets.
Foreign currency translation	'
	Foreign currency translation:  All balance sheet accounts have been translated using the exchange rates in effect at the balance sheet date.  Statement of income amounts have been translated using the average exchange rate for the year.  The gains and losses resulting from the changes in exchange rates from year to year have been reported in other comprehensive income (loss).  The foreign currency translation adjustment is the only component of accumulated other comprehensive loss.  Foreign currency translation adjustments exclude income tax expense (benefit) given that the Company’s investments in foreign subsidiaries are deemed to be reinvested for an indefinite period of time.
Revenue recognition	'
	Revenue recognition: The Company primarily records revenue from product sales when the revenue is realized and the product is shipped from its facilities.  This includes satisfying the following criteria: the arrangement with the customer is evident, usually through the receipt of a purchase order; the sales price is fixed and determinable; delivery to the carrier has occurred; and collectability is reasonably assured. Freight and insurance billed to customers is included in net sales, and the cost of freight and insurance is included in cost of sales.  Sales tax billed to customers is included as a liability as products are shipped.
	The terms and conditions of sales to both the Company’s domestic and international distributors do not differ materially from the terms and conditions of sales to its domestic and international end-user customers.
	Service revenue substantially relates to repairs of products and is recognized when the service has been completed.  Revenue from royalty fees is recorded as the products bearing the trademark are shipped.
Advertising	'
	Advertising: The Company follows the policy of charging the costs of advertising to expense as incurred. Advertising expense was approximately $197,000, $146,000 and $153,000 for the years ended July 31, 2014, 2013 and 2012, respectively.
Royalties	'
	Royalties: The Company pays royalties to doctors and medical institutions for providing assistance in the design and development of various devices and components.  Royalties are paid quarterly based on the sales of the instrument or components.  Royalty expense was approximately $346,000, $331,000 and $282,000 for the years ended July 31, 2014, 2013 and 2012, respectively.
Stock compensation	'
	Stock compensation: The Company has a stock plan for employees and consultants allowing for the grant of incentive and non-qualified stock options, restricted stock and stock awards. In addition, the Company has a stock option plan for non-employee directors allowing for non-qualified stock options.  Options under this plan have been granted to all non-employee directors.  Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the directors’ and employees’ requisite service periods. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options and grant-date market value to determine the fair value of the restricted stock awards.
Earnings per share	'
	Earnings per share: Basic earnings per share data has been computed on the basis of the weighted average number of common shares outstanding during each period presented.  Diluted earnings per share data has been computed on the basis of the assumed conversion, exercise or issuance of all potential common stock instruments, unless the effect is to reduce the loss or increase the net income per common share (dollars in thousands, except share and per share data):
			Year Ended July 31,
			2014		2013		2012
	Numerator:
	Income from continuing operations		$	3,063	$	2,559	$	5,968
	Loss from discontinued operations net of income tax			--		--		382
	Net income			3,063		2,559		5,586
	Denominator:
	Weighted average common shares and denominator for basic calculation			25,323,622		25,243,010		25,100,064
	Stock options			69,642		94,515		156,520
	Denominator for diluted calculation			25,393,264		25,337,525		25,256,584
	Earnings per share – basic
	Income from continuing operations		$	0.12	$	0.1	$	0.24
	Loss from discontinued operations			--		--		(0.02	)
	Net income		$	0.12	$	0.1	$	0.22
	Earnings per share – diluted
	Income from continuing operations		$	0.12	$	0.1	$	0.24
	Loss from discontinued operations			0		0		(0.02	)
	Net income		$	0.12	$	0.1	$	0.22
	Stock option shares excluded from computation of dilutive income per share because the effect would be antidilutive for the years ended July 31, 2014, 2013 and 2012 were 650,579, 533,079 and 215,734, respectively.
Segment reporting	'
	Segment reporting: Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief decision maker or group in deciding how to allocate resources and in assessing performance.  The Company’s chief decision maker reviews the results of operations and requests for capital expenditures based on one industry segment: producing and selling products and procedures for surgery, primarily for vitreoretinal surgery and neurosurgery.  The Company’s entire revenue is generated through this segment.  Revenues are attributed to countries based upon the location of end-user customers or distributors.
Reclassifications	'
	Reclassifications: Certain reclassifications have been made to the prior year financial statements to conform to the current year’s presentation.

Nature_of_Business_and_Signifi2

Nature of Business and Significant Accounting Policies (Tables)	12 Months Ended
	Jul. 31, 2014
Nature of Business and Significant Accounting Policies [Abstract]	'
Estimated useful lives of property and equipment	'
	Property and equipment are depreciated using the straight-line method over their estimated useful lives as follows:
		Useful lives (in years)
	Building and improvements	Jul-39
	Machinery and equipment	7-May
	Furniture and fixtures	7-May
	Software	10-Mar
Deferred revenue	'
	The Company recognized $1.3 million, $1.3 million and $1.2 million of this deferred revenue for the fiscal years ended July 31, 2014, 2013 and 2012, respectively.
			31-Jul-14		31-Jul-13
	Deferred revenue – Alcon settlement		$	14,530	$	15,818
	Less:  Short-term			1,288		1,288
	Long-term portion		$	13,242	$	14,530
Calculation of numerator and denominator in earnings per share	'
	Basic earnings per share data has been computed on the basis of the weighted average number of common shares outstanding during each period presented.  Diluted earnings per share data has been computed on the basis of the assumed conversion, exercise or issuance of all potential common stock instruments, unless the effect is to reduce the loss or increase the net income per common share (dollars in thousands, except share and per share data):
			Year Ended July 31,
			2014		2013		2012
	Numerator:
	Income from continuing operations		$	3,063	$	2,559	$	5,968
	Loss from discontinued operations net of income tax			--		--		382
	Net income			3,063		2,559		5,586
	Denominator:
	Weighted average common shares and denominator for basic calculation			25,323,622		25,243,010		25,100,064
	Stock options			69,642		94,515		156,520
	Denominator for diluted calculation			25,393,264		25,337,525		25,256,584
	Earnings per share – basic
	Income from continuing operations		$	0.12	$	0.1	$	0.24
	Loss from discontinued operations			--		--		(0.02	)
	Net income		$	0.12	$	0.1	$	0.22
	Earnings per share – diluted
	Income from continuing operations		$	0.12	$	0.1	$	0.24
	Loss from discontinued operations			0		0		(0.02	)
	Net income		$	0.12	$	0.1	$	0.22

Exit_Costs_Tables

Exit Costs (Tables)	12 Months Ended
	Jul. 31, 2014
Exit Costs [Abstract]	'
Exit costs	'
		Twelve Months					Cumulative		Total
	(dollars in thousands)	Ended July 31,					as of July 31,		Expected to
		2014			2013		2014		be Incurred
	Employee termination costs	$	615		$	--	$	615	$	1,085
	Other associated costs		67			--		67		79
		$	682		$	--	$	682	$	1,164
		Termination Costs
	Exit liabilities at August 1, 2013	$	--
	Additions		682
	Payments/settlements		(570	)
	Exit liabilities at July 31, 2014	$	112

Discontinued_Operations_Tables

Discontinued Operations (Tables)	12 Months Ended
	Jul. 31, 2014
Discontinued Operations [Abstract]	'
Discontinued operations	'
	The following table summarizes the results of the discontinued operations fiscal years ended July 31, 2014, 2013 and 2012 (dollars in thousands):
		Year Ended July 31
		2014		2013		2012
	Net sales	$	--	$	--	$	23
	Operating costs		--		--		(191	)
	Impairment, restructuring and other charges		--		--		(253	)
	Write-off of goodwill		--		--		(29	)
	Loss on sale of fixed assets		--		--		(125	)
	Loss from discontinued operations before benefit for income taxes		--		--		(575	)
	Income tax benefit		--		--		193
	Loss from discontinued operations	$	--	$	--	$	(382	)

OEM_Partner_Agreements_Tables

OEM Partner Agreements (Tables)	12 Months Ended
	Jul. 31, 2014
OEM Partner Agreements [Abstract]	'
Total sales to marketing partners and their respective percent of the Company's net sales	'
	Codman
	Total sales to Codman and its respective percent of the Company’s net sales for the years ended July 31, 2014, 2013 and 2012, including the historical sales of generators, accessories and disposable cord tubing that the Company has supplied in the past, as well as the disposable bipolar forceps sales resulting from the addendum to the existing distribution agreement, were as follows (dollars in thousands):
		Year Ended July 31,
		2014			2013			2012
	Net sales	$	15,173		$	14,097		$	11,150
	Percent of net sales		23.4	%		22.4	%		18.6	%
	Stryker Corporation (“Stryker”)
	Total sales to Stryker and its respective percent of the Company’s net sales for the years ended July 31, 2014, 2013 and 2012, including the historical sales of pain control generators, and accessories that the Company has supplied in the past, as well as the disposable ultrasonic aspirator instrument tips sales and certain other consumable products resulting from the new agreements, were as follows (dollars in thousands):
		Year Ended July 31,
		2014			2013			2012
	Net sales	$	10,779		$	10,815		$	10,398
	Percent of net sales		16.6	%		17.2	%		17.3	%

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Jul. 31, 2014
Inventories [Abstract]	'
Inventories	'
	Inventories as of July 31, 2014 and 2013 were as follows (dollars in thousands):
		2014		2013
	Raw material and component parts	$	5,900	$	7,418
	Work in progress		2,077		1,133
	Finished goods		7,157		6,274
		$	15,134	$	14,825

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Jul. 31, 2014
Property and equipment [Abstract]	'
Property and equipment	'
	Property and equipment as of July 31, 2014 and 2013 were as follows (dollars in thousands):
		2014		2013
	Land	$	984	$	730
	Building and improvements		6,650		6,365
	Machinery and equipment		9,023		8,665
	Furniture and fixtures		1,182		1,058
	Software		1,113		1,107
	Construction in progress		153		177
			19,105		18,102
	Less accumulated depreciation		10,320		9,140
		$	8,785	$	8,962

Other_Intangible_Assets_Tables

Other Intangible Assets (Tables)	12 Months Ended
	Jul. 31, 2014
Other Intangible Assets [Abstract]	'
Information regarding other intangible assets	'
	Information regarding the Company’s other intangible assets is as follows (dollars in thousands):
		Gross Carrying		Accumulated		Net
		Value		Amortization
		31-Jul-14
	Proprietary know-how	$	4,208	$	2,208	$	2,000
	Trademark		5,944		--		5,944
	Licensing agreement		5,694		2,895		2,799
	Other intangibles		1,279		111		1,168
	Patents		2,375		903		1,472
		$	19,500	$	6,117	$	13,383
		31-Jul-13
	Proprietary know-how	$	3,707	$	1,936	$	1,771
	Trademark		5,938		--		5,938
	Licensing agreement		5,694		2,626		3,068
	Other intangibles		938		--		938
	Patents		2,087		676		1,411
		$	18,364	$	5,238	$	13,126

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Jul. 31, 2014
Accrued Expenses [Abstract]	'
Accrued expenses	'
	Accrued expenses as of July 31, 2014 and 2013 consisted of the following (dollars in thousands):
		2014		2013
	Payroll, commissions and employee benefits	$	1,402	$	1,737
	Operations/services		832		1,421
	Taxes other than income		611		328
		$	2,845	$	3,486

Operating_Leases_Tables

Operating Leases (Tables)	12 Months Ended
	Jul. 31, 2014
Operating Leases [Abstract]	'
Approximate minimum rental commitment under non-cancelable operating leases	'
	The approximate minimum rental commitment under non-cancelable operating leases as of July 31, 2014 is due as follows (dollars in thousands):
	Year Ending July 31,	Amount
	2015	$	394
	2016		173
	2017		75
	2018		26
	2019		--
		$	668

Income_Tax_Matters_Tables

Income Tax Matters (Tables)	12 Months Ended
	Jul. 31, 2014
Income Tax Matters [Abstract]	'
Deferred income tax assets and liabilities	'
	The Company and its wholly owned subsidiaries file as a single entity for income tax reporting purposes.  The net deferred income tax amounts included in the accompanying consolidated balance sheets as of July 31, 2014 and 2013 include the following amounts as deferred income tax assets and liabilities (dollars in thousands):
		2014			2013
	Deferred tax assets:
	Accounts receivable	$	204		$	119
	Inventories		1,002			847
	Accrued liabilities		173			186
	Deferred revenue		5,456			5,940
	Other		172			133
	Loss on foreign subsidiaries		1,720			2,080
	Valuation allowance		(1,720	)		--
			7,007			9,305
	Deferred tax liability
	Property and equipment		960			1,561
	Other intangible assets		2,786			2,360
			3,746			3,921
		$	3,261		$	5,384
	The deferred tax amounts noted above have been classified on the accompanying consolidated balance sheets as of July 31, 2014 and 2013, as follows (dollars in thousands):
		2014			2013
	Current assets	$	2,042		$	1,827
	Long-term asset		1,219			3,557
		$	3,261		$	5,384
Provision for income taxes	'
	The provision for income taxes for the years ended July 31, 2014, 2013 and 2012, consisted of the following (dollars in thousands):
		2014			2013			2012
	Current (receivable) payable	$	(338	)	$	1,179		$	2,153
	Deferred		1,836			(49	)		153
		$	1,498		$	1,130		$	2,306
Reconciliation of income tax at statutory rate to effective rate	'
	Reconciliation of the Company’s income tax at the statutory rate to the Company’s effective rate is as follows:
		2014			2013			2012
	Computed at the statutory rate		34	%		34	%		34	%
	State taxes, net of federal tax benefit		2.4			2.5			2.4
	Foreign rate differential		(3.2	)		--			--
	Production deduction for domestic manufacturers		(2.0	)		(4.3	)		(2.9	)
	Research and experimentation		(1.6	)		(5.3	)		(0.8	)
	Other		3.2			3.7			(3.2	)
			32.8	%		30.6	%		29.5	%

StockBased_Compensation_Plans_

Stock-Based Compensation Plans (Tables)	12 Months Ended
	Jul. 31, 2014
Stock-Based Compensation Plans [Abstract]	'
Stock options activity	'
	A summary of the status of the fixed awards at July 31, 2014, 2013 and 2012 and changes during the years ended on those dates is as follows:
		Shares			Weighted				Weighted
					Average				Average Fair
					Exercise				Value
					Price
	Options outstanding, July 31, 2011		517,029		$	2.68			$	2.16
	Granted		235,734		$	6.21			$	4.75
	Forfeited		(56,133	)	$	4.11			$	3.22
	Exercised		(16,885	)	$	2.07			$	1.99
	Options outstanding, July 31, 2012		679,745		$	3.8			$	2.98
	Granted		142,227		$	4.52			$	3.42
	Forfeited		(15,000	)	$	4.54			$	3.66
	Exercised		(59,310	)	$	1.1			$	0.95
	Options outstanding, July 31, 2013		747,662		$	3.23			$	4.17
	Granted		117,500		$	3.64			$	2.72
	Forfeited		--			--				--
	Exercised		(50,000	)	$	1.17			$	0.97
	Options outstanding July 31, 2014		815,162		$	4.25			$	3.27
	Options exercisable, July 31, 2014		582,299		$	4.1			$	3.18
	A further summary of the awards outstanding at July 31, 2014 is as follows:
		Shares			Weighted Average
					Grant Date Value
	Unvested options, beginning of period		233,211		$	3.84
	Granted		117,500		$	2.72
	Vested		(117,848	)	$	3.4
	Forfeited		--			--
	Unvested options, period end		232,863		$	3.5
Proceeds, related tax benefits realized from options exercised and intrinsic value of options exercised	'
	Proceeds, related tax benefits realized from options exercised and the intrinsic value of options exercised were as follows (dollars in thousands), except exercise price:
		Fiscal Year Ended
		31-Jul-14			31-Jul-13				31-Jul-12
	Proceeds of options exercised	$	59		$	65			$	35
	Related tax benefit recognized		38			72				24
	Intrinsic value of options exercised		48			56				34
Weighted average remaining life for options outstanding and weighted average exercise price per share for exercisable options	'
	The following table provides information about options outstanding and exercisable options at July 31, 2014 (dollars in thousands):
		Options			Exercisable
		Outstanding			Options
	Number		815,162			582,299
	Weighted average exercise price	$	4.25		$	4.1
	Aggregate intrinsic value	$	3,464		$	2,387
	Weighted average contractual term	6.5 years			5.8 years
	The weighted average remaining life for options outstanding and weighted average exercise price per share for exercisable options at July 31, 2014 were as follows:
			Options Outstanding				Exercisable Options
			Shares		Weighted Average		Shares			Weighted Average
					Remaining					Remaining
					Contractual Life (in					Contractual Life (in
					years)					years)
	<$ 2.00			124,583	5.0 years			117,583		5.0 years
	$ 2.01 to $3.00			40,000	3.3 years			40,000		3.3 years
	$ 3.01 to $4.00			157,500	7.6 years			64,792		5.1 years
	$ 4.01 to $5.00			257,345	6.8 years			196,800		6.5 years
	$ 5.01 to $6.21			235,734	6.8 years			163,124		6.6 years
	Total			815,162	6.5 years			582,299		5.8 years
Assumptions used to derive weighted average fair value of options granted	'
	The following table provides the assumptions used in the Black-Scholes model:
		Fiscal Year Ended July 31,
		2014			2013				2012
	Expected average risk-free interest rate		2.9	%		1.72	%			1.92	%
	Expected average life (in years)		10			10				10
	Expected volatility		68.6	%		70.5	%			71.4	%
	Expected dividend yield		0	%		0	%			0	%
Information about restricted stock grants	'
	The following table provides information about restricted stock awards during the fiscal year ended July 31, 2014, 2013 and 2012:
		Number of Shares			Weighted Average
					Grant Date Fair Value
	Balance as of August 1, 2011		310,707		$	2.38
	Granted		202,072			6.37
	Forfeited		(39,384	)		5.88
	Vested		(41,617	)		3.47
	Balance as of July 31, 2012		431,778			3.82
	Granted		70,307			4.52
	Forfeited		(10,160	)		3.47
	Vested		(86,677	)		4.57
	Balance as of July 31, 2013		405,248			3.79
	Granted		7,000			3.38
	Forfeited		(2,335	)		3.88
	Vested		(134,366	)		4.52
	Balance as of July 31, 2014		275,547			3.42
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	'
	Compensation expense associated with stock-based compensation plans as of July 31, 2014, 2013 and 2012 was as follows (dollars in thousands):
		31-Jul-14			31-Jul-13				31-Jul-12
	Stock Options:
	Directors	$	163		$	230			$	217
	Employees		364			233				154
	Total	$	527		$	463			$	371
	Restricted Stock
	Employees	$	426		$	413			$	357
	Advisors		55			55				36
	Total		481			468				393
	Total Compensation Expense	$	1,008		$	931			$	764
	Income Tax benefits from Share-based Compensation	$	331		$	285			$	225

Enterprisewide_Sales_Informati1

Enterprise-wide Sales Information (Tables)	12 Months Ended
	Jul. 31, 2014
Enterprise-wide Sales Information [Abstract]	'
Enterprise-wide sales information	'
	Enterprise-wide sales information as of July 31, 2014, 2013 and 2012 consisted of the following (dollars in thousands):
			Fiscal Year Ended July 31,
			2014		2013		2012
	Net Sales
	Ophthalmic		$	35,242	$	35,446	$	35,240
	OEM (1)			28,671		26,469		23,973
	Other (2)			856		881		801
	Total		$	64,769	$	62,796	$	60,014
			Fiscal Year Ended July 31,
			2014		2013		2012
	Net Sales
	Domestic		$	48,407	$	46,489	$	44,047
	International			16,362		16,307		15,967
	Total		$	64,769	$	62,796	$	60,014
		-1	Net sales from OEM represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel generators, disposable ultrasonic tips and related accessories to Stryker, and sales of certain disposable products. Recognition of deferred revenues of $1.3 million from Alcon is included in this category for the fiscal years ended July 31, 2014 and 2013, and recognition of deferred revenues of $266,000 and $1.2 million from Codman and Alcon, respectively, are included in this category for the fiscal year ended July 31, 2012.
		-2	Net sales from Other represent direct neurosurgery revenues and other miscellaneous revenues.

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Jul. 31, 2014
Quarterly Financial Data (Unaudited) [Abstract]	'
Summary of quarterly financial information	'
	The following table provides the Company’s quarterly information as presented in the Form 10-Q (dollars in thousands except share and per share data):
	Quarters ended:	July 31,		April 30,		January 31,			October 31,
		2014*		2014		2014			2013
	Net sales	$	18,008	$	16,135	$	15,096		$	15,530
	Gross profit		9,995		8,912		8,398			8,924
	Operating income		2,156		1,411		(377	)		1,391
	Net income		1,410		943		(225	)		935
	Earnings per share - basic	$	0.06	$	0.04	$	(0.01	)	$	0.04
	Earnings per share - diluted	$	0.06	$	0.04	$	(0.01	)	$	0.04
	Basic weighted average common shares outstanding		25,352,326		25,331,925		25,309,641			25,294,020
	Diluted weighted average common shares outstanding		25,400,341		25,392,782		25,309,641			25,389,940
	Quarters ended:	July 31,		April 30,		January 31,			October 31,
		2013**		2013		2013			2012
	Net sales	$	17,857	$	16,264	$	14,055		$	14,620
	Gross profit		9,676		9,051		5,171	***		8,473
	Operating income		2,212		1,721		(2,153	)		1,941
	Net income		1,439		1,150		(1,382	)		1,352
	Earnings per share – basic	$	0.06	$	0.05	$	(0.05	)	$	0.05
	Earnings per share – diluted	$	0.06	$	0.05	$	(0.05	)	$	0.05
	Basic weighted average common shares outstanding		25,290,882		25,299,131		25,230,142			25,160,757
	Diluted weighted average common shares outstanding		25,367,558		25,362,923		25,230,142			25,286,184
	*        The acquisition of the private OEM company has been reflected in our results of operations from May 3, 2014, the date of the acquisition.
	**      The M.I.S.S. acquisition has been reflected in our results of operations from July 8, 2013, the date of the acquisition.
	***    In the second quarter of fiscal 2013, the Company recorded an inventory write-down of approximately $2.1 million, or approximately $0.06 per share, net of tax.

Nature_of_Business_and_Signifi3

Nature of Business and Significant Accounting Policies (Details) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

Jul. 31, 2014

Apr. 30, 2014

Jan. 31, 2014

Oct. 31, 2013

Jul. 31, 2013

Apr. 30, 2013

Jan. 31, 2013

Oct. 31, 2012

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2012

Apr. 30, 2010

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2010

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Segment

Alcon Settlement [Member]

Alcon Settlement [Member]

Alcon Settlement [Member]

Alcon Settlement [Member]

Alcon Settlement [Member]

Codman Exclusivity [Member]

Codman Exclusivity [Member]

Codman Exclusivity [Member]

Building and improvements [Member]

Building and improvements [Member]

Machinery and equipment [Member]

Machinery and equipment [Member]

Furniture and fixtures [Member]

Furniture and fixtures [Member]

Software [Member]

Software [Member]

Other Intangible Assets [Member]

Other Intangible Assets [Member]

Product

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Inventory [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventory reserves

'

'

'

'

'

'

$1,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'7 years

'39 years

'5 years

'7 years

'5 years

'7 years

'3 years

'10 years

'3 years

'15 years

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of patents

'

'

'

'

'

'

'

'

876,000

680,000

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Revenue Arrangement [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful life

'

'

'

'

'

'

'

'

'

'

'

'15 years

'12 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred revenue

'

'

'

'

'

'

'

'

'

'

'

'

14,530,000

15,818,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Less: Short-term portion

1,288,000

'

'

'

1,288,000

'

'

'

1,288,000

1,288,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term portion

13,242,000

'

'

'

14,530,000

'

'

'

13,242,000

14,530,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue recognized

'

'

'

'

'

'

'

'

'

'

'

'

1,300,000

1,300,000

1,200,000

'

0

0

266,000

'

'

'

'

'

'

'

'

'

'

Proceeds from Confidential Settlement and License Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Confidential Settlement and License Agreement, net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain on agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Up-front license fee

11,911,000

'

'

'

11,715,000

'

'

'

11,911,000

11,715,000

'

19,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of products cancelled

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated earning period

'

'

'

'

'

'

'

'

'

'

'

'15 years

'12 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Standard Product Warranty Disclosure [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Typical warranty period (in years)

'

'

'

'

'

'

'

'

'3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Marketing and Advertising Expense [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advertising Expense

'

'

'

'

'

'

'

'

197,000

146,000

153,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating Costs and Expenses [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty expense

'

'

'

'

'

'

'

'

346,000

331,000

282,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Numerator:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income from continuing operations

'

'

'

'

'

'

'

'

3,063,000

2,559,000

5,968,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Plus: Loss from discontinued operations - net of tax

'

'

'

'

'

'

'

'

0

0

382,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net income

$1,410,000

[1]

$943,000

($225,000)

$935,000

$1,439,000

[2]

$1,150,000

($1,382,000)

$1,352,000

$3,063,000

$2,559,000

$5,586,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Denominator:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average common shares and denominator for basic calculation (in shares)

25,352,326

[1]

25,331,925

25,309,641

25,294,020

25,290,882

[2]

25,299,131

25,230,142

25,160,757

25,323,622

25,243,010

25,100,064

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options (in shares)

'

'

'

'

'

'

'

'

69,642

94,515

156,520

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Denominator for diluted calculation (in shares)

25,400,341

[1]

25,392,782

25,309,641

25,389,940

25,367,558

[2]

25,362,923

25,230,142

25,286,184

25,393,264

25,337,525

25,256,584

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Antidilutive securities excluded from computation of earnings per share (in shares)

'

'

'

'

'

'

'

'

650,579

533,079

215,734

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Earnings per share - basic

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income from continuing operations (in dollars per share)

'

'

'

'

'

'

'

'

$0.12

$0.10

$0.24

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss from discontinued operations (in dollars per share)

'

'

'

'

'

'

'

'

$0

$0

($0.02)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net income (in dollars per share)

$0.06

[1]

$0.04

($0.01)

$0.04

$0.06

[2]

$0.05

($0.05)

$0.05

$0.12

$0.10

$0.22

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Earnings per share - diluted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income from continuing operations (in dollars per share)

'

'

'

'

'

'

'

'

$0.12

$0.10

$0.24

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss from discontinued operations (in dollars per share)

'

'

'

'

'

'

'

'

$0

$0

($0.02)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net income (in dollars per share)

$0.06

[1]

$0.04

($0.01)

$0.04

$0.06

[2]

$0.05

($0.05)

$0.05

$0.12

$0.10

$0.22

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of operating segments

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

The acquisition of the private OEM company has been reflected in our results of operations from May 3, 2014, the date of the acquisition.

[2]

The M.I.S.S. acquisition has been reflected in our results of operations from July 8, 2013, the date of the acquisition.

Exit_Costs_Details

Exit Costs (Details) (USD $)	12 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012
Exit Costs [Abstract]	'	'	'
Current liability related to employee termination benefits	$112,000	$0	'
Exit Costs [Line Items]	'	'	'
Exit costs, incurred	682,000	0	'
Exit costs, cumulative	682,000	'	'
Exit costs, expected to be incurred	1,164,000	'	'
Termination Costs [Abstract]	'	'	'
Exit Liabilities, beginning of period	0	'	'
Additions	682,000	0	0
Payments/settlements	-570,000	'	'
Exit Liabilities, end of period	112,000	0	'
Employee Termination Benefits [Member]	'	'	'
Exit Costs [Line Items]	'	'	'
Exit costs, incurred	615,000	0	'
Exit costs, cumulative	615,000	'	'
Exit costs, expected to be incurred	1,085,000	'	'
Other Associated Costs [Member]	'	'	'
Exit Costs [Line Items]	'	'	'
Exit costs, incurred	67,000	0	'
Exit costs, cumulative	67,000	'	'
Exit costs, expected to be incurred	$79,000	'	'

Acquisitions_Details

Acquisitions (Details) (USD $)	12 Months Ended						0 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2014	Mar. 31, 2013	Jul. 31, 2013	3-May-14	3-May-14
				M.I.S.S. Ophthalmics Limited [Member]	M.I.S.S. Ophthalmics Limited [Member]	M.I.S.S. Ophthalmics Limited [Member]	Ophthalmology Manufacturing Company [Member]	Ophthalmology Manufacturing Company [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Cash consideration	'	'	'	$2,800,000	'	'	$1,400,000	'
Contribution to revenue due to wholesale distribution activities	'	'	'	1,100,000	'	'	'	'
Total revenue	64,769,000	62,796,000	60,014,000	'	3,200,000	'	'	'
Intellectual property	'	'	'	900,000	'	'	'	800,000
Goodwill	12,738,000	12,155,000	'	1,500,000	'	'	'	400,000
Transaction related costs	'	'	'	$64,000	'	$70,000	'	'

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012
Discontinued Operations [Abstract]	'	'	'
Net Sales	$0	$0	$23
Operating costs	0	0	-191
Impairment, restructuring and other charges	0	0	-253
Write-off of goodwill	0	0	-29
Loss on sale of fixed assets	0	0	-125
Loss from discontinued operations before benefit for income taxes	0	0	-575
Income tax benefit	0	0	193
Loss from discontinued operations	$0	$0	($382)

OEM_Partner_Agreements_Details

OEM Partner Agreements (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012
	Partner
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Number of U.S. based national and international marketing partners	2	'	'
Net sales	$64,769	$62,796	$60,014
Reporting threshold (in hundredths)	10.00%	'	'
Codman collaborative arrangement [Member]	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Numbers of years a product was sold	'30 years	'	'
Net sales	15,173	14,097	11,150
percent of net sales (in hundredths)	23.40%	22.40%	18.60%
Codman collaborative arrangement [Member] | Bipolar generators and related disposables and accessories [Member]	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaborative arrangement time frame	'3 years	'	'
Collaborative arrangements extension	'3 years	'	'
Codman collaborative arrangement [Member] | Malis Spetzler Trademark [Member]	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaborative arrangement time frame	'3 years	'	'
Collaborative arrangements extension	'3 years	'	'
Stryker collaborative arrangement [Member]	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Net sales	$10,779	$10,815	$10,398
percent of net sales (in hundredths)	16.60%	17.20%	17.30%

Inventories_Details

Inventories (Details) (USD $)	Jul. 31, 2014	Jul. 31, 2013
In Thousands, unless otherwise specified
Inventories [Abstract]	'	'
Raw material and component parts	$5,900	$7,418
Work in progress	2,077	1,133
Finished goods	7,157	6,274
Inventory, net	$15,134	$14,825

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	$19,105	$18,102	'
Less accumulated depreciation	10,320	9,140	'
Property and equipment, net	8,785	8,962	'
Depreciation expense	1,173	1,123	1,093
Land [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	984	730	'
Building and improvements [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	6,650	6,365	'
Machinery and equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	9,023	8,665	'
Furniture and fixtures [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	1,182	1,058	'
Software [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	1,113	1,107	'
Construction in progress [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and equipment, gross	$153	$177	'

Other_Intangible_Assets_Detail

Other Intangible Assets (Details) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

Sep. 21, 2005

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2012

3-May-14

Jul. 08, 2013

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2014

Jul. 31, 2013

Ophthalmology Manufacturing Company [Member]

M.I.S.S. [Member]

Proprietary Know-How [Member]

Proprietary Know-How [Member]

Trademark [Member]

Trademark [Member]

Licensing Agreement [Member]

Licensing Agreement [Member]

Other Intangibles [Member]

Other Intangibles [Member]

Patents [Member]

Patents [Member]

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross Carrying Value

'

$19,500,000

$18,364,000

'

'

'

$4,208,000

$3,707,000

$5,944,000

$5,938,000

$5,694,000

$5,694,000

$1,279,000

$938,000

$2,375,000

$2,087,000

Accumulated Amortization

'

6,117,000

5,238,000

'

'

'

2,208,000

1,936,000

0

0

2,895,000

2,626,000

111,000

0

903,000

676,000

Net

'

13,383,000

13,126,000

'

'

'

2,000,000

1,771,000

5,944,000

5,938,000

2,799,000

3,068,000

1,168,000

938,000

1,472,000

1,411,000

Goodwill acquired

10,700,000

'

'

'

439,000

1,500,000

'

'

'

'

'

'

'

'

'

'

Other intangible assets acquired

3,700,000

'

'

'

765,000

900,000

'

'

'

'

'

'

'

'

'

'

Amortization included in general and administrative expense

'

876,000

680,000

600,000

'

'

'

'

'

'

'

'

'

'

'

'

Future amortization expense [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2015

'

975,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2016

'

975,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2017

'

975,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2018

'

975,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2019

'

$975,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Jul. 31, 2014	Jul. 31, 2013
In Thousands, unless otherwise specified
Accrued Expenses [Abstract]	'	'
Payroll, commissions and employee benefits	$1,402	$1,737
Operations/services	832	1,421
Taxes other than income	611	328
Accrued expenses	$2,845	$3,486

Pledged_Assets_Short_and_LongT1

Pledged Assets, Short and Long-Term Debt (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Jul. 31, 2014
Line of Credit Facility [Line Items]	'
Minimum fixed charge coverage ratio	1.25
Revolving Credit Facility [Member]	'
Line of Credit Facility [Line Items]	'
Maximum borrowing capacity	9.5
Description of variable rate basis	'The one-, two- or three-month LIBOR
Basis spread on variable rate (in hundredths)	1.75%
Interest rate at period end (in hundredths)	1.98%
Interest charge on unused portion of facility (in hundredths)	0.20%
Borrowings under credit facility	0
Maturity date	30-Sep-16
Number of financial covenants	2
Maximum leverage ratio	2.25
Leverage ratio	0
Fixed charge coverage ratio	352
Equipment Line of Credit [Member]	'
Line of Credit Facility [Line Items]	'
Maximum borrowing capacity	1
Description of variable rate basis	'One-month LIBOR
Basis spread on variable rate (in hundredths)	3.00%
Minimum interest rate (in hundredths)	3.50%
Borrowings under credit facility	0
Maturity date	30-Sep-16

Operating_Leases_Details

Operating Leases (Details) (USD $)	12 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012
Approximate minimum rental commitment under non-cancelable operating leases [Abstract]	'	'	'
2015	$394,000	'	'
2016	173,000	'	'
2017	75,000	'	'
2018	26,000	'	'
2019	0	'	'
Total	668,000	'	'
Rent expense	$457,000	$364,000	$353,000

Income_Tax_Matters_Details

Income Tax Matters (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012
Deferred tax assets:	'	'	'
Accounts receivable	$204	$119	'
Inventories	1,002	847	'
Accrued liabilities	173	186	'
Deferred revenue	5,456	5,940	'
Other	172	133	'
Loss on foreign subsidiaries	1,720	2,080	'
Valuation allowance	-1,720	0	'
Deferred tax assets	7,007	9,305	'
Deferred tax liability	'	'	'
Property and equipment	960	1,561	'
Other intangible assets	2,786	2,360	'
Deferred tax liability	3,746	3,921	'
Deferred tax assets (liability), net	3,261	5,384	'
Deferred tax amounts classified on consolidated balance sheets	'	'	'
Current assets	2,042	1,827	'
Long-term asset	1,219	3,557	'
Deferred tax amounts	3,261	5,384	'
Provision for income taxes [Abstract]	'	'	'
Current (receivable) payable	-338	1,179	2,153
Deferred	1,836	-49	153
Provision for income taxes	$1,498	$1,130	$2,306
Reconciliation of income tax at statutory rate to effective rate [Abstract]	'	'	'
Computed at the statutory rate (in hundredths)	34.00%	34.00%	34.00%
State taxes, net of federal tax benefit (in hundredths)	2.40%	2.50%	2.40%
Foreign rate differential (in hundredths)	-3.20%	0.00%	0.00%
Production deduction for domestic manufacturers (in hundredths)	-2.00%	-4.30%	-2.90%
Research and experimentation (in hundredths)	-1.60%	-5.30%	-0.80%
Other (in hundredths)	3.20%	3.70%	-3.20%
Effective income tax rate (in hundredths)	32.80%	30.60%	29.50%

Employee_Benefit_Plan_Details

Employee Benefit Plan (Details) (USD $)	12 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012
Employee Benefit Plan [Abstract]	'	'	'
Minimum age required for 401(k) savings plan	'18 years	'	'
Requisite service period for 401(k) savings plan	'1 year	'	'
Company's contribution to the plan	$120,000	$203,000	$79,000

StockBased_Compensation_Plans_1

Stock-Based Compensation Plans (Details) (USD $)

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2014

Jul. 31, 2014

Jan. 31, 2014

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2012

Jan. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2012

Jul. 31, 2014

Jul. 31, 2014

Sep. 19, 2005

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Jul. 31, 2014

Sep. 19, 2005

Jul. 31, 2014

Less than 2.00 [Member]

2.01 to 3.00 [Member]

3.01 to 4.00 [Member]

4.01 to 5.00 [Member]

5.01 to 6.21 [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

2001 Stock Plan [Member]

2001 Stock Plan [Member]

2001 Stock Plan [Member]

2001 Stock Plan [Member]

2001 Stock Plan [Member]

2005 Non-Employee Directors' Plan [Member]

2005 Non-Employee Directors' Plan [Member]

2005 Non-Employee Directors' Plan [Member]

Minimum [Member]

Maximum [Member]

Directors [Member]

Directors [Member]

Directors [Member]

Directors [Member]

Employees [Member]

Employees [Member]

Employees [Member]

Officers [Member]

Officers [Member]

Advisors [Member]

Advisors [Member]

Advisors [Member]

Employees [Member]

Employees [Member]

Employees [Member]

Officers [Member]

Plan

Stock Options [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Stock Options [Member]

Advisors [Member]

Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of existing active option plans prior to merger

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

Number of terminated option plans prior to merger

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

Shares authorized (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

700,000

'

Aggregate number of available for future grant (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

629,484

'

'

'

'

285,000

'

'

Term

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period

'

'

'

'

'

'

'

'

'

'

'

'3 years

'5 years

'

'12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options, number of shares [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options outstanding, beginning of period (in shares)

'

'

'

'

'

'

'

'

747,662

679,745

517,029

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in shares)

'

'

'

'

'

'

'

'

117,500

142,227

235,734

'

'

60,000

'

'

'

'

'

'

57,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Forfeited (in shares)

'

'

'

'

'

'

'

'

0

-15,000

-56,133

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercised (in shares)

'

'

'

'

'

'

'

'

-50,000

-59,310

-16,885

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options outstanding, end of period (in shares)

'

'

'

'

'

'

'

'

815,162

747,662

679,745

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options exercisable, end of period (in shares)

'

'

'

'

'

'

'

'

582,299

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation related to exit costs

$682,000

$0

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$201,000

'

'

'

'

'

'

'

'

Options, weighted average exercise price [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options outstanding, beginning of period (in dollars per share)

'

'

'

'

'

'

'

'

$3.23

$3.80

$2.68

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in dollars per share)

'

'

'

'

'

'

'

'

$3.64

$4.52

$6.21

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Forfeited (in dollars per share)

'

'

'

'

'

'

'

'

$0

$4.54

$4.11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercised (in dollars per share)

'

'

'

'

'

'

'

'

$1.17

$1.10

$2.07

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options outstanding, end of period (in dollars per share)

'

'

'

'

'

'

'

'

$4.25

$3.23

$3.80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options exercisable, end of period (in dollars per share)

'

'

'

'

'

'

'

'

$4.10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options, weighted average fair value [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options outstanding, beginning of period (in dollars per share)

'

'

'

'

'

'

'

'

$4.17

$2.98

$2.16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in dollars per share)

'

'

'

'

'

'

'

'

$2.72

$3.42

$4.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Forfeited (in dollars per share)

'

'

'

'

'

'

'

'

$0

$3.66

$3.22

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercised (in dollars per share)

'

'

'

'

'

'

'

'

$0.97

$0.95

$1.99

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options outstanding, end of period (in dollars per share)

'

'

'

'

'

'

'

'

$3.27

$4.17

$2.98

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options exercisable, end of period (in dollars per share)

'

'

'

'

'

'

'

'

$3.18

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested options, number of shares [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested options, beginning of period (in shares)

'

'

'

'

'

'

'

'

233,211

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in shares)

'

'

'

'

'

'

'

'

117,500

142,227

235,734

'

'

60,000

'

'

'

'

'

'

57,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested (in shares)

'

'

'

'

'

'

'

'

-117,848

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Forfeited (in shares)

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested options, period end (in shares)

'

'

'

'

'

'

'

'

232,863

233,211

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested options, weighted average grant date value [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested options, beginning of period (in dollars per share)

'

'

'

'

'

'

'

'

$3.84

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in dollars per share)

'

'

'

'

'

'

'

'

$2.72

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested (in dollars per share)

'

'

'

'

'

'

'

'

$3.40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Forfeited (in dollars per share)

'

'

'

'

'

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unvested options, period end (in dollars per share)

'

'

'

'

'

'

'

'

$3.50

$3.84

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds, related tax benefits and intrinsic value of options exercised [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds of options exercised

'

'

'

'

'

'

'

'

59,000

65,000

35,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related tax benefit recognized

'

'

'

'

'

'

'

'

38,000

72,000

24,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intrinsic value of options exercised

'

'

'

'

'

'

'

'

48,000

56,000

34,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional information about options outstanding [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number (in shares)

'

'

'

'

'

'

'

'

815,162

747,662

679,745

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average exercise price (in dollars per share)

'

'

'

'

'

'

'

'

$4.25

$3.23

$3.80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value

'

'

'

'

'

'

'

'

3,464,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average contractual term

'

'

'

'

'

'

'

'

'6 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional information about exercisable options [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number (in shares)

'

'

'

'

'

'

'

'

582,299

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average exercise price (in dollars per share)

'

'

'

'

'

'

'

'

$4.10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value

'

'

'

'

'

'

'

'

2,387,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average contractual term

'

'

'

'

'

'

'

'

'5 years 9 months 18 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

Compensation expense related to current year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

24,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assumptions used to derive weighted average fair value of options granted [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected average risk-free interest rate (in hundredths)

'

'

'

'

'

'

'

'

2.90%

1.72%

1.92%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected average life

'

'

'

'

'

'

'

'

'10 years

'10 years

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected volatility (in hundredths)

'

'

'

'

'

'

'

'

68.60%

70.50%

71.40%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected dividend yield (in hundredths)

'

'

'

'

'

'

'

'

0.00%

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of U.S. Treasury yield curve used to estimate average risk-free interest rate

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future compensation cost expected to be recognized [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fiscal 2014

324,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fiscal 2015

238,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fiscal 2016

119,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fiscal 2017

17,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to non-vested share-based compensation arrangements granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

580,000

'

'

'

'

Weighted average period for recognition of unrecognized compensation cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

Compensation expenses

1,008,000

931,000

764,000

'

'

'

'

'

527,000

463,000

371,000

'

'

'

163,000

230,000

217,000

364,000

233,000

154,000

'

'

481,000

468,000

393,000

55,000

55,000

36,000

426,000

413,000

357,000

'

'

'

55,000

'

'

'

'

'

Restricted stock grants, number of shares [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock awards, beginning of period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

405,248

431,778

310,707

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,000

70,307

202,072

'

'

'

'

'

'

'

'

'

'

'

14,648

'

'

'

Vested (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-134,366

-86,677

-39,384

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Forfeited (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,335

-10,160

-41,617

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

End of period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

275,547

405,248

431,778

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Grant Date Fair Value [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock awards, beginning of period (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.79

$3.82

$2.38

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.38

$4.52

$6.37

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vested (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.52

$4.57

$5.88

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Forfeited (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.88

$3.47

$3.47

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

End of period (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.42

$3.79

$3.82

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation expense associated with stock-based compensation plans [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation Expense

1,008,000

931,000

764,000

'

'

'

'

'

527,000

463,000

371,000

'

'

'

163,000

230,000

217,000

364,000

233,000

154,000

'

'

481,000

468,000

393,000

55,000

55,000

36,000

426,000

413,000

357,000

'

'

'

55,000

'

'

'

'

'

Income Tax benefits from Share-based Compensation

$331,000

$285,000

$225,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price range, lower range limit (in dollars per share)

'

'

'

'

$2.01

$3.01

$4.01

$5.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price range, upper range limit (in dollars per share)

'

'

'

$2

$3

$4

$5

$6.21

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of outstanding options (in shares)

815,162

'

'

124,583

40,000

157,500

257,345

235,734

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options outstanding, weighted average remaining contractual life

'6 years 6 months

'

'

'5 years

'3 years 3 months 18 days

'7 years 7 months 6 days

'6 years 9 months 18 days

'6 years 9 months 18 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of exercisable options (in shares)

582,299

'

'

117,583

40,000

64,792

196,800

163,124

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable options, weighted average remaining contractual life

'5 years 9 months 18 days

'

'

'5 years

'3 years 3 months 18 days

'5 years 1 month 6 days

'6 years 6 months

'6 years 7 months 6 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	12 Months Ended
	Jul. 31, 2014	Jul. 31, 2013	Sep. 22, 2005	Sep. 21, 2005
Stockholders' Equity [Abstract]	'	'	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00	$0.00	$0.01
Common stock, shares authorized (in shares)	50,000,000	50,000,000	50,000,000	'
Common stock, voting rights	'Each share of common stock is entitled to one vote on any matter submitted to the holders	'	'	'

Research_and_Development_Costs1

Research and Development Costs (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012
Research and Development Costs [Abstract]	'	'	'
R&D costs incurred	$5,158	$3,643	$3,642

Enterprisewide_Sales_Informati2

Enterprise-wide Sales Information (Details) (USD $)	12 Months Ended
	Jul. 31, 2014		Jul. 31, 2013		Jul. 31, 2012
Revenue from External Customer [Line Items]	'		'		'
Net sales	$64,769,000		$62,796,000		$60,014,000
Revenues from External Customers [Line Items]	'		'		'
Net sales	64,769,000		62,796,000		60,014,000
Alcon [Member]	'		'		'
Revenues from External Customers [Line Items]	'		'		'
Recognition of deferred revenue	1,300,000		1,300,000		1,200,000
Codman exclusivity [Member]	'		'		'
Revenues from External Customers [Line Items]	'		'		'
Recognition of deferred revenue	'		'		266,000
Domestic [Member]	'		'		'
Revenues from External Customers [Line Items]	'		'		'
Net sales	48,407,000		46,489,000		44,047,000
International [Member]	'		'		'
Revenues from External Customers [Line Items]	'		'		'
Net sales	16,362,000		16,307,000		15,967,000
Ophthalmic [Member]	'		'		'
Revenue from External Customer [Line Items]	'		'		'
Net sales	35,242,000		35,446,000		35,240,000
OEM [Member]	'		'		'
Revenue from External Customer [Line Items]	'		'		'
Net sales	28,671,000	[1]	26,469,000	[1]	23,973,000	[1]
Other [Member]	'		'		'
Revenue from External Customer [Line Items]	'		'		'
Net sales	$856,000	[2]	$881,000	[2]	$801,000	[2]
[1]	Net sales from OEM represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel generators, disposable ultrasonic tips and related accessories to Stryker, and sales of certain disposable products. Recognition of deferred revenues of $1.3 million from Alcon is included in this category for the fiscal years ended July 31, 2014 and 2013, and recognition of deferred revenues of $266,000 and $1.2 million from Codman and Alcon, respectively, are included in this category for the fiscal year ended July 31, 2012.
[2]	Net sales from Other represent direct neurosurgery revenues and other miscellaneous revenues.

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (Change in Control Agreement [Member])	12 Months Ended
	Jul. 31, 2014
Change in Control Agreement [Member]	'
Change in Control [Line Items]	'
Time frame for agreement to expire after the change of control	'1 year
Time frame to enter into a separation agreement after termination	'30 days
Number of years of base salary to be paid per agreement	'1 year
Number of monthly equal installments to be paid after termination	'12 months
Time frame for all awards to be exercised after termination	'1 year

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data (Unaudited) (Details) (USD $)

3 Months Ended

12 Months Ended

Jul. 31, 2014

Apr. 30, 2014

Jan. 31, 2014

Oct. 31, 2013

Jul. 31, 2013

Apr. 30, 2013

Jan. 31, 2013

Oct. 31, 2012

Jul. 31, 2014

Jul. 31, 2013

Jul. 31, 2012

Quarterly Financial Data (Unaudited) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

Net sales

$18,008,000

[1]

$16,135,000

$15,096,000

$15,530,000

$17,857,000

[2]

$16,264,000

$14,055,000

$14,620,000

'

'

'

Gross Profit

9,995,000

[1]

8,912,000

8,398,000

8,924,000

9,676,000

[2]

9,051,000

5,171,000

[3]

8,473,000

36,229,000

32,371,000

34,519,000

Operating Income

2,156,000

[1]

1,411,000

-377,000

1,391,000

2,212,000

[2]

1,721,000

-2,153,000

1,941,000

4,581,000

3,721,000

8,481,000

Net income

1,410,000

[1]

943,000

-225,000

935,000

1,439,000

[2]

1,150,000

-1,382,000

1,352,000

3,063,000

2,559,000

5,586,000

Earnings per share - basic (in dollars per share)

$0.06

[1]

$0.04

($0.01)

$0.04

$0.06

[2]

$0.05

($0.05)

$0.05

$0.12

$0.10

$0.22

Earnings per share - diluted (in dollars per share)

$0.06

[1]

$0.04

($0.01)

$0.04

$0.06

[2]

$0.05

($0.05)

$0.05

$0.12

$0.10

$0.22

Basic weighted average common shares outstanding (in share)

25,352,326

[1]

25,331,925

25,309,641

25,294,020

25,290,882

[2]

25,299,131

25,230,142

25,160,757

25,323,622

25,243,010

25,100,064

Diluted weighted average common shares outstanding (in share)

25,400,341

[1]

25,392,782

25,309,641

25,389,940

25,367,558

[2]

25,362,923

25,230,142

25,286,184

25,393,264

25,337,525

25,256,584

Income from continuing operations

'

'

'

'

'

'

'

'

3,063,000

2,559,000

5,968,000

Loss from discontinued operations

'

'

'

'

'

'

'

'

0

0

-382,000

Earnings per share - basic

'

'

'

'

'

'

'

'

'

'

'

Income from continuing operations (in dollars per share)

'

'

'

'

'

'

'

'

$0.12

$0.10

$0.24

Loss from discontinued operations (in dollars per share)

'

'

'

'

'

'

'

'

$0

$0

($0.02)

Earnings per share - diluted

'

'

'

'

'

'

'

'

'

'

'

Income from continuing operations (in dollars per share)

'

'

'

'

'

'

'

'

$0.12

$0.10

$0.24

Loss from discontinued operations (in dollars per share)

'

'

'

'

'

'

'

'

$0

$0

($0.02)

Inventory Write-down

'

'

$2,100,000

'

'

'

'

'

'

'

'

Earnings per share (in dollars per share)

'

'

$0.06

'

'

'

'

'

'

'

'

[1]

The acquisition of the private OEM company has been reflected in our results of operations from May 3, 2014, the date of the acquisition.

[2]

The M.I.S.S. acquisition has been reflected in our results of operations from July 8, 2013, the date of the acquisition.

[3]

In the second quarter of fiscal 2013, the Company recorded an inventory write-down of approximately $2.1 million, or approximately $0.06 per share, net of tax.

Valuation_Allowances_and_Quali1

Valuation Allowances and Qualifying Accounts (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012
Allowance for Doubtful Accounts & Returned Goods [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at Beginning of Year	$495	$319	$282
Charges to Cost and Expenses	338	207	37
Charges to Other Accounts	0	0	0
Deduction from Reserves	111	31	0
Balance at End of Year	722	495	319
Allowance for Excess and Obsolete Inventory [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Balance at Beginning of Year	1,834	466	82
Charges to Cost and Expenses	383	1,368	384
Charges to Other Accounts	0	0	0
Deduction from Reserves	0	0	0
Balance at End of Year	$2,217	$1,834	$466